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ABSTRACT 
The breast is the leading cancer site and the first or second cause of malignancy-
associated death in women in Western societies. The reason for rapid growth of this 
disease is complex but reflects the socio-economic development, ageing and growth 
of the population. Substantial evidence on the potential risk factors has been 
developed, and mammography screening has been identified as an important public 
health measure for early detection of the disease. An important risk factor, ‘breast 
symptoms’ reported by women at screening visits are not always evaluated 
adequately, or information regarding the symptoms are left out by many screening 
programmes. This thesis seek to generate novel evidence on possible breast cancer 
outcomes in these women.  
This thesis is composed of four sub-studies that used individual level data 
available from various registries in Finland. In the first part of the thesis, we discuss 
how we measured the mammography-screening programme performance indicators 
in relation to breast symptoms. We found a higher recall proportion and higher 
cancer detection rate in women with symptoms as compared to those without 
symptoms. The sensitivity and positive predictive value (PPV) of the lump was 
higher than that of retraction and nipple discharge. Mammography test sensitivity 
and PPVs were higher for visits with a lump or retraction but not for visits with 
nipple discharge.   
The second cohort study estimated the cumulative probability of false-positive 
test and false-positive referrals and compared visits with and without symptoms. The 
cumulative risk of a false-positive test after 10 screening visits was 45% for a lump, 
retraction 25% and nipple discharge 35% as compared to about 18% in visits without 
symptoms. Likewise, we found higher cumulative risk of a false-positive referral in 
all symptom types as compared to respective asymptomatic visits.  
In the third phase, we assessed the risk of screen-detected and interval breast 
cancers in relation to breast symptoms. The age-adjusted risk of screen-detected 
invasive breast cancer in visits with a lump was 8 times higher, retraction 2.4 times 
higher and nipple discharge 1.7 times higher than the respective visits without 
symptoms. The risk was 22 times higher if both a lump and retraction were reported 
in the same visit. Interval cancer risk was assessed by matching symptomatic visits 
with asymptomatic visits by background variables. We found a strong positive 
association between symptoms and the risk of interval breast cancer. The cumulative 
incidence of interval cancers increased rapidly after a screening visit with a lump.  
Finally, we assessed the risk of breast cancer mortality and all-cause mortality by 
symptom types and compared them with asymptomatic visits. The breast cancer 
mortality rate was very high within the first five years after screening visits with a 
lump or retraction. The risk of breast cancer mortality was elevated for women with 
a lump or retraction. We found an increased all-cause mortality for all symptom types 
as compared to the respective asymptomatic visit.  
Our findings can be applied to various steps in the monitoring of programme 
performance up to the evaluation of outcomes and health equities. Our study 
showed the importance of collecting and analysing information on breast symptoms. 
It is important to continuously improve the awareness of breast symptoms in 
women, with the advice being to seek care even prior to invitations. High-quality and 
clinically appropriate services are important for women presenting with symptoms 
at screening mammography. Our findings indicate the need to improve the 
guidelines for screening and clinical services for women with symptoms. Further 
assessment is needed more frequently, including appropriate biopsy. Improved 
systematic surveillance or follow-up of symptomatic women who did not undergo 
further assessment is crucial.  
 
 
TIIVISTELMÄ 
Rintasyöpä on naisten tavallisin syöpätyyppi ja yleisin tai toiseksi yleisin syövästä 
johtuva kuolinsyy länsimaissa. Taudin nopeaan kasvuun on monia syitä, jotka 
heijastavat sosioekonomista kehitystä, ikääntymistä ja väestönkasvua. Mahdollisista 
riskitekijöistä on saatavilla paljon tutkimustietoa, ja väestöpohjaisen 
mammografiaseulonnan on todettu olevan tärkeä keino taudin havaitsemiseksi 
varhaisessa vaiheessa. Tärkeitä riskitekijöitä ovat naisten seulontakäynneillä 
ilmoittamat ”rintaoireet”, joita ei kuitenkaan aina arvioida riittävän hyvin tai joita 
koskevia tietoja ei laisinkaan kerätä seulontaohjelmassa. Tämä väitöstutkimus pyrkii 
esittämään uutta näyttöä näiden naisten rintasyöpiä koskevista tuloksista.  
Työ koostuu neljästä osatutkimuksesta, joissa on hyödynnetty erilaisia 
rekisteriperäisiä yksilötasoisia tietoja. Tutkimuksen ensimmäisessä osassa selvitimme 
mammografiaohjelman toimivuutta kuvaavien mittareiden suhdetta rintaoireisiin. 
Totesimme, että naiset, joilla oli oireita, heidät kutsuttiin useammin jatkotutkimuksiin 
ja heillä havaittiin useammin syöpä kuin oireettomilla naisilla. Kyhmyjen herkkyys ja 
positiivinen ennustearvo (PPV) olivat suurempia kuin vetäymien ja nännieritteiden. 
Mammografiatutkimuksen herkkyys ja PPV-arvot olivat suurempia, kun käyntiin 
liittyi kyhmy tai vetäymä, mutta ei silloin kun kyseessä oli nännierite.  
Toisessa kohorttitutkimuksessa arvioitiin väärän positiivisen tuloksen ja väärän 
positiivisen lähetteen kumulatiivista todennäköisyyttä ja verrattiin oireisia ja 
oireettomia käyntejä. Naisilla, joilla oli todettu kyhmy vähintään kerran, väärän 
positiivisen testituloksen kumulatiivinen riski kymmenen seulontakäynnin jälkeen oli 
45 %, ja vastaava arvio oli 25 % vetäymälle ja 35 % nännieritteelle. Vastaava luku 
oireettomille käynneille oli noin 18 %. Tämän perusteella totesimme, että väärän 
positiivisen lähetteen kumulatiivinen riski oli suurempi kaikissa oiretyypeissä 
verrattuna vastaavaan oireettomaan käyntiin.  
Kolmannessa vaiheessa arvioimme seulonnassa havaittujen ja seulontakertojen 
välillä havaittujen rintasyöpien riskiä suhteessa rintaoireisiin. Seulonnassa havaitun 
rintasyövän ikävakioitu riski käynneillä, joihin liittyi kyhmy, vetäymä tai nännierite oli 
vastaavasti 8 kertaa, 2,4 kertaa ja 1,7 kertaa suurempi kuin käynneillä, joihin ei liittynyt 
oireita. Riski oli 22 kertaa suurempi, jos samalla käynnillä todettiin sekä kyhmy että 
vetäymä. Seulontakertojen välillä ilmenevien syöpien riskiä arvioitiin vertaamalla 
oireisia ja oireettomia käyntejä taustamuuttujien avulla. Oireiden ja seulontakertojen 
välisen rintasyövän riskin välillä oli vahva positiivinen yhteys. Välisyöpien 
kumulatiivinen ilmaantuvuus lisääntyi seulonnan jälkeen nopeasti, kun 
seulontakäynnnilä oli todettu kyhmy.  
Lopuksi arvioimme rintasyöpäkuolleisuuden ja kaikista syistä johtuvan 
kuolleisuuden riskiä oiretyyppien mukaan ja vertasimme niitä oireettomiin 
käynteihin. Rintasyövästä johtuva kuolleisuusaste oli hyvin korkea viiden vuoden 
sisällä seulontakäynnistä, johon liittyi kyhmy tai vetäymä. Rintasyövästä aiheutuvan 
kuoleman riski oli korkeampi, kun käyntiin liittyi kyhmy tai vetäymä, mutta ei silloin 
kun käyntiin liittyi erite nännistä. Kaikista syistä aiheutuva kuolleisuus pysyi 
suurempana kaikissa oiretyypeissä verrattuna vastaavaan oireettomaan käyntiin.  
Havaintojamme voidaan soveltaa eri vaiheisiin ohjelman toimivuuden 
seurannasta aina tulosten ja terveyden samanarvoisuuden arviointiin saakka. 
Tutkimuksemme osoitti, kuinka tärkeää on kerätä ja analysoida tietoa rintaoireista. 
On tärkeää lisätä jatkuvasti tietoisuutta naisten rintaoireista ja neuvoa hakeutumaan 
hoitoon jo ennen kutsuja. Laadukkaat ja kliinisesti asianmukaiset palvelut ovat 
tärkeitä naisille, joiden mammografiaseulontaan liittyy oireita. Tuloksemme 
osoittavat, että on tarpeen kehittää seulontaa ja kliinisiä palveluita koskevia ohjeita 
oireisille naisille. Jatkotutkimuksia, mm. soveltuvia kudosnäytteitä, tarvitaan nykyistä 
useammin. On myös erittäin tärkeää seurata seulontaohjelman yhteydessä 
systemaattisesti rintaoireisia naisia, mikäli heille ei tehty jatkotutkimuksia.  
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1 INTRODUCTION 
In the 21st-century, cancer is expected to rank as the leading cause of death and the 
single most important barrier for increasing life expectancy in every country of the 
world. Breast cancer is the most frequently diagnosed cancer (154 out of 185 
countries) and the most common cause of malignancy-associated death in women in 
over 100 countries (Bray et al., 2018). In Finland, the incidence of this disease 
continued to rise over decades, while mortality has shown a slight decrease in recent 
years. Considering the high prevalence of this disease, efforts to reduce deaths are 
globally an urgent public health priority. 
A substantial amount of evidence has been accumulated on the natural history 
and burden of the disease. In recent decades, efforts have been put into both primary 
and secondary preventive measures by identifying the potential risk factors and with 
organized breast cancer screening programmes. Evidence from randomized- 
controlled trials and observation studies have shown to reduce breast cancer 
mortality by about 40% in those who underwent mammography screening (Lauby-
Secretan et al., 2015). On the other hand, advancement in modern chemotherapy 
and adjuvant treatment have improved the survival of women with breast cancer. A 
lot of these improvements are not uniform across countries or geographical areas, 
even within the same country. Existing socio-economic inequalities, several 
individual risk factors, evolvement of new risk factors due to so-called westernization 
of lifestyle, and the ageing and growth of the population have all led to the prominent 
differences in the rates as observed in different countries.   
Countries with existing screening programmes that act as a part of routine health 
policy invite all women in the targeted age, irrespective of individual history. 
However, based on the evidence generated in recent decades through 
epidemiological and biomedical research, several studies have proposed personalized 
screening modalities for women who are at a higher risk of a breast cancer diagnosis. 
A noticeable proportion (about 3% in the Finnish programme) of women present 
with clinically significant symptoms at the screening visit. A majority of, if not all 
service screening programmes that offer mammography services to the whole target 
population refer women presenting with symptoms either directly to breast clinics 
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or to general practitioners for further consultation. A proportion of women are left 
out by the programme and, hence, information about breast symptoms is not 
collected or analysed. One important reason is that many programmes lack proper 
guidelines on screening and clinical services for women presenting with breast 
symptoms. As well, EU guidelines on breast cancer screening do not have specific 
recommendations for referral procedures for these women (Perry et al., 2006). Most 
of the women in the Finnish programme presenting with symptoms such as a lump, 
retraction or nipple discharge (also identified as ‘urgent referrals’ in the UK screening 
guidelines) (Mansel et al., 1999) likely do not undergo further assessment and are 
systematically followed-up in the programme up to cancer diagnosis or death. This 
presents the opportunity for research to generate novel evidence on possible cancer 
outcomes in these women.  
 The objective of this study was to identify the importance of analysing breast 
symptoms in the Finnish mammography screening programme, measured in terms 
of programme performance indicators and breast cancer outcomes up to mortality 
outcomes in those women. This helps create an evidence-based guideline and 
develop a potential screening and clinical service strategies that might improve the 
potential screening outcomes for women presenting with breast symptoms at the 
screening visit.  
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2 LITERATURE REVIEW 
2.1 Epidemiology of breast cancer 
2.1.1 Breast cancer burden  
Breast cancer is the most frequently diagnosed tumour disease in women in both 
developed and less-developed regions with an age-standardized rate (ASR) of 75.4 
per 100000 and 31.3 per 100000 women respectively (Globocan, 2012; Key et al., 
2001). Incidence rates are higher in Europe and Northern America than in other 
regions but are increasing. According to the American Cancer Society, one in eight 
women will develop breast cancer in her lifetime (DeSantis et al., 2014). More than 
one million new breast cancer cases are diagnosed each year (Ferlay et al., 2015; 
Forman et al., 2014) with greater variation in the incidence between different regions 
(Figure 1, below) (Globocan, 2012). In the Nordic countries from 2000 – 2015, the 
incidence ASR has increased from 79 to 86.8 per 100,000 women, while the mortality 
ASR has decreased from 18.3 to 12.2 per 100,000 women respectively (Engholm et 
al., 2018). Figure 2 shows the time-trend of breast cancer incidence and mortality in 
Finland from 1953-2016. In Finland, the age-standardized incidence increased from 
75 to 94 per 100,000 women during 1998 – 2015, while the mortality rates declined 
from 15 to 13 per 100,000 women in the same period (Finnish Cancer Registry, 
2018c). In 2016, 4961 breast cancers incidents and 888 deaths were registered at the 
Finnish Cancer Registry. The five-year relative survival of breast cancer patients was 
91% (95% CI 90.5-92.0).   
     The worldwide increase in life-expectancy and continuing demographic and 
epidemiological transition, particularly in less developed regions, signal the ever-
increasing burden of the disease over the next decades (Ferlay et al., 2015). While 
the incidence of disease is high in Western countries, the mortality-to-incidence ratio 
(MIR) is high in low-income countries; the MIR ratio of 0.69 in Africa as compared 
to 0.19 in North America, for example (Forouzanfar et al., 2011). The westernization 
of the developing world is the main force behind the increase in incidence rates, 
which encompasses adoption of less desirable habits including lifestyle and 
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behavioural factors (P. Porter, 2008), whereas in the developed countries, 
enhancement in early detection and treatment of breast cancer have resulted in a 
decrease in the mortality rates and continual increase in the five-year survival of the 
disease. However, facilities are uncommon in low-and middle-income countries, 
leading to late-stage presentation of disease, and resulting in higher case fatality rates 
and a lower rate of survival.  
 
Figure 1.  Estimated age-standardized rates (ASR, World) rates of breast cancer per 100,000 
women 
Source: GLOBOCAN 2012 (IARC), Section of Cancer Surveillance (Accessed 
08.08.2018) http://globocan.iarc.fr/Pages/bar_site_sel.aspx  
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Figure 2.  Time trends of breast cancer incidence and mortality in Finland in 1953-2016, age-
standardized (World) rates per 100000 women 
Source: Finnish Cancer Registry, Cancer Statistics (Accessed 04.01.2018) 
https://cancerregistry.fi/statistics/cancer-statistics/ 
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2.1.2 Aetiology of breast cancer 
Breast cancer is a complex, highly heterogeneous disease at both the molecular and 
clinical level with multifactorial causations and multiple sub-types (Perou et al., 2000; 
Sorlie et al., 2001). The disease has more than one natural history, thus cancer 
progression stages from atypia to carcinoma in situ, invasive cancer and metastasis - 
may not hold true for all cases (Buerger et al., 1999; Buerger et al., 2001). A common 
and acceptable understanding is that the epithelial proliferation, both ductal and 
lobular is associated with benign disease, while atypia confers an increased risk of 
developing breast cancer (IARC, 2002). Substantial evidence has been developed on 
the experimental, clinical and epidemiological aspects of breast cancer, providing 
better understanding of its aetiology. As well, the introduction of screening 
mammography has led to a significant improvement in the overall prognosis, a shift 
in tumour stage and survival in breast cancer patients. In parallel, many strong risk 
factors have been recognized. 
2.1.2.1 Risk factors 
Several causal factors of breast cancer have been established in the pathways of 
disease progression, mainly based on tumour heterogeneity, which in turn is mainly 
related to morphology, gene expression and clinical outcomes (Patel, 2018; Perou et 
al., 2000; Polyak, 2007; Polyak, 2011). The interaction of these factors together with 
established risk factors causes the risk profile change in women. This had led to a 
failure in identifying the exact subset of women in whom the majority of breast 
cancer arises (IARC, 2016). Many of the risk factors prevalent in high-income 
countries are well established and evident through epidemiological studies. Of these, 
age is the single most pronounced risk factor for breast cancer. The incidence rises 
rapidly till 50 years of age after that, one sees about a 5% increase in cumulative 
incidence (in Europe) till age 75 (IARC, 2016; Key et al., 2001). Beside age, several 
non-modifiable and modifiable risk factors, including hormonal and reproductive 
factors, life-style and environmental factors, are described below in Table 1. 
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Table 1.  Selected list of established risk factors of breast cancer 
Risk factor Categories Direction References 
Hormonal and reproductive 
factors 
Younger age at menarche Increased risk (Anderson et al.,  2014; Colditz et 
al., 2000)  
Younger age at first birth Decreased risk (IARC, 2016; Anderson et al., 
2014; Barnard et al., 2015) 
Older age at menopause Increased risk (Colditz et al., 2000; 
Collaborative Group on 
Hormonal Factors in Breast 
Cancer, 2012) 
Postmenopausal HRT Increased risk (Barnard et al., 2015; IARC, 
2012; Ritte et al., 2012) 
Oral contraceptives Increased risk (IARC, 2012) 
Breast feeding Decreased risk (Barnard et al., 2015; 
Collaborative Group on 
Hormonal Factors in Breast 
Cancer, 2002; Islami et al., 2015) 
Parity Decreased risk (Anderson et al., 2014; Colditz et 
al., 2000; Collaborative Group on 
Hormonal Factors in Breast 
Cancer, 2002) 
Lifestyle factors and 
environmental exposures 
 
Alcohol intake Increased risk (Allen et al., 2009; IARC, 2012; 
National Cancer Institute, 2018; 
Seitz et al., 2012) 
Adult BMI Increased risk (Arnold et al., 2015; WCRF, 
2018) 
Post-menopausal, obesity Increased risk (Key et al., 2001) 
Physical activity Decreased risk (Pizot et al., 2016; WCRF, 2018; 
Wu et al., 2013) 
Tobacco smoking Increased risk (Catsburg et al., 2015; Cui et al., 
2006; IARC, 2012; Lauby-
Secretan et al., 2009) 
Non-modifiable risk factors Age (>50 years old) Increased risk (Anderson et al., 2006) 
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Breast density Increased risk (Chiu et al., 2010; Kerlikowske et 
al., 2007; Pettersson et al., 2014) 
Family history of breast cancer  Increased risk (Anderson et al., 2000; Barnard 
et al., 2015; Collaborative Group 
on Hormonal Factors in Breast 
Cancer, 2001) 
Benign breast disease Increased risk (Colditz et al., 2000; Hartmann et 
al., 2005) 
Chest radiation at younger age Increased risk (Henderson et al., 2010; 
Moskowitz et al., 2014) 
2.1.2.2 Risk factors by mode of detection 
The mode of cancer detection, mainly screen-detected and interval cancers may be 
an important factor in identifying the subset of women if the risk factors differ 
between these sub-types. Performance and evaluation indicators of screening 
programmes are influenced by the interval cancer; thus, understanding the risk 
factors for interval cancer is crucial for a programme to detect cancer in the 
preclinical phase (IARC, 2016). Studies have found that women who have high 
mammography density, and/or current users of hormonal therapy and/or have 
previously been diagnosed with benign breast disease have higher risk of interval 
cancers than screen-detected cancers (Blanch et al., 2014; Domingo et al., 2014; 
Kirsh et al., 2011; Pollan et al., 2013). In postmenopausal women, the breast is 
usually fattier, which make lesions easier to detect by mammography, and, hence, 
more cancers are diagnosed during the screening visits (Surakasula et al., 2014). 
Hormonal therapy prolongs the density of the breast, which may then disguise the 
findings in the mammography; this may lead to an increase in interval cancers 
(Collaborative group on Hormonal Factors in Breast Cancer, 1997; Beral et al., 
2003). A study in the USA found that a higher proportion of rapidly proliferating 
and aggressive cancers in younger women were diagnosed as interval cancers 
(Gilliland et al., 2000). Another study in Finland found higher interval cancer rates 
in younger women but no difference in the cell proliferation rate between women 
younger than 50 and older women (Klemi et al., 1997). The parametrisation of family 
history showed no clear direction across studies. However, there is no existing valid 
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approach for identifying the subset of women based on established risk factors; 
hence, age-related invitation is still the single best screening strategy (IARC, 2016).  
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2.1.3 Natural history of breast cancer 
In recent years, an increase in the understanding at the molecular and tissue levels 
suggests that breast cancer is the result of an imbalance in the complex regulatory 
cycles to which breast tissue is exposed (Tkaczuk et al., 2017). The up and down 
regulation of hormones and epidermal growth influences the genetic pathways, 
leading to cell proliferation and regression (Georgian-Smith et al., 2014). The real 
action takes place at the interface between perceived cancer cells and the presumably 
normal tissues adjacent to those cells. This mechanism forms an early genetic 
predisposition that alters the cellular and physiological phenotypic traits, which 
explains the apparent paradox of the natural history of cancer (Lakhani et al., 2012). 
The ductal and lobular epithelial proliferation and hyperplasia causes benign disease, 
which confers an increased risk of developing breast cancer. More than 95% of 
breast tumours arise from the epithelial cell lining of the breast, from either the milk-
producing glands (lobular carcinomas) or the draining ducts (ductal carcinomas) 
(Erban et al., 2010; IARC, 2002).  
      The heterogeneous nature of breast cancer forms more than one natural 
history; thus, the idea of a natural progression of cancer from atypia to carcinoma in 
situ, invasive cancer and metastasis may not actually be certainly true (Buerger et al., 
1999; Buerger et al., 2001). The disease has an enigmatic time-variable history, with 
long, disease-free intervals followed by cyclic recurrence and remission. Despite the 
variability of disease progression, the degree of malignancy of individual tumours 
can be predicted with reasonable accuracy. The two most important factors for the 
prognosis of breast cancers are the extent of spread or stage of the tumour and its 
degree of differentiation or grade. A tumour with better prognosis is confined to the 
breast itself (stage I) and well differentiated (grade I), whereas one that has spread to 
the axillary lymph nodes (stage II and III) and is very poorly differentiated (grade 
III) results in a poor prognosis (Lakhani et al., 2012)  
     The natural course of breast cancer progression has three main points: benign 
disease, in situ carcinoma and invasive cancer. Understanding the progression rates 
is crucial for answering the question about how intensively the abnormalities should 
be sought and treated (IARC Handbook - Breast Cancer Screening, 2002). The 
widespread use of mammographic screening typically aimed at early detection during 
the detectable pre-clinical phase has altered the natural history of the disease (Figure 
3). Thus, the time interval between the onset of disease and the diagnosis of disease 
(also known as detectable pre-clinical phase or sojourn time) has decreased. 
Correspondingly, the period when a cancer is found by screening and when it would 
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appear through clinical signs and symptoms, also known as lead time, has increased. 
However, the increase or decrease in the time interval is affected by the frequency 
of screening, characteristics of lesions and the screening test. A screening 
mammography detects many forms of breast cancer, ranging from low-grade DCIS 
to large, high-grade, invasive cancer; thus, this technique is well recognized to 
prevent the development of high-grade, invasive cancer (Cowan et al., 1991; Evans 
et al., 1997; Evans, 2001a; Evans, 2001b; Klemi et al., 1992; Lampejo et al., 1994; 
Rajakariar et al., 1995; Walker et al., 1994). The rate of progression at each stage of 
disease defines the mean sojourn time (MST) and permits a range of behaviours (Tan 
et al., 2013). Duffy et al. (1995) used the two-parameter Markov chain model to 
estimate the MST using the data from a Swedish two-country study (Duffy et al., 
1995). They found that the estimate of MST ranging from 2.1 to 2.5 years. The lead 
time following the introduction of digital screening tools has become longer than 
with analogue mammography. The frequency of screening and increase in life 
expectancy also affects the lead time (IARC, 2002). While the low-grade tumours 
identified at screening with excellent prognosis may be indolent, some might 
progress over time to become aggressive. No method or technique has yet been 
developed for clinical verification of the over diagnosed cancers. The size, nodal 
involvement and metastases (TNM) of these tumours defines the disease prognosis, 
and eventually the success of breast cancer screening programmes.  
 
 
Figure 3.  Scheme of progression of cancer, with intervention of screening test for early detection 
(A) Natural history progression of breast cancer; (B) Disease progression after 
intervention by screening  
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2.2 Screening for breast cancer 
While the ultimate goal of breast cancer screening is to reduce mortality from the 
disease among the screened women, the immediate goal is to detect cancer at the 
detectable pre-clinical phase or asymptomatic phase (IARC, 2016). Early detection 
together with early access to effective treatment services, helps achieve the greater 
effect of screening (Lauby-Secretan et al., 2015). The European Parliament in June 
2003 called for the EU member states to develop and implement effective screening 
strategies for improved preventive health care. Until now, screening by 
mammography has been identified as the most popular means of screening women 
for breast cancer. Screening, diagnostic and treatment services are provided at the 
population level through organized programs in high-income countries. Among the 
EU member states 25 countries have ongoing, piloted or planned population-based 
breast cancer screening programmes targeting 50-69 years old (Ponti et al., 2017).  
The screening programmes are evaluated based on the set criteria for the process 
indicators of screening mentioned in the European guidelines for mammography 
screening (Perry et al., 2006). Some upper middle-income countries offer service 
through either organized or opportunistic screening, whereas low- and middle-
income countries promote breast cancer awareness or clinical breast examination as 
a means for early detection of the disease (IARC, 2016; Lauby-Secretan et al., 2015). 
Organized screening programmes are based on firm evidence regarding the 
effectiveness and appropriate balance between screening benefits and harm (Ponti 
et al., 2017). The implementation of screening programmes can either be population-
based - if the people in the eligible target population in the selected area served by 
the programme are individually identified and personally invited to attend screening 
- or performed in a diagnostic or clinical context mainly referred to by general 
practitioners as so called ‘grey’, ‘wild’, or ‘opportunistic’ testing (Arbyn et al., 2010; 
Ponti et al., 2017). In several European countries, including Finland, screening by 
mammography for breast cancer is run as part of public health policy (Hakama et 
al., 1997). Evidence of screening with other screening modalities or imaging 
techniques at the population level is limited or inadequate in terms of reduction in 
mortality from the disease. Some studies have evaluated the effectiveness of other 
imaging techniques, such as ultrasonography or magnetic resonance imaging 
together with mammography, in women with an increased risk of breast cancer (Bick 
et al., 2019; Wilczek et al., 2016).   
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2.2.1 Impact of screening mammography on breast cancer incidence and 
mortality 
Evidence from the randomised, controlled trials conducted in the 1980s and 1990s 
(Andersson et al., 1988; Tabár et al., 1992, Bjurstam et al., 2003; Moss et al., 2005; 
Autier et al., 2009), and the recent cohort and case-controls studies (Moss, 1999; 
Ascunce et al., 2007; Weedon-Fekjær et al., 2014; Morrison et al., 1988; Hofvind et 
al., 2013) report a clear reduction in breast cancer mortality in women invited to or 
who attended organized mammography screening. In 2014, the IARC (International 
Agency for Research on Cancer) expert working group evaluated the scientific 
evidence reported by the clinical trials and high-quality observational studies on the 
effectiveness of mammographic screening programmes (Lauby-Secretan et al., 
2015). The working group concluded that a clear reduction in breast cancer mortality 
was evident in women aged 50-69 years who attended the mammographic screening. 
The mortality reduction in women aged 50-69 years who were invited for a 
mammography screening was about 23%, and the mortality risk reduction in women 
who attended the mammography screening was about 40% (Ascunce et al., 2007; 
Hakama et al., 1997; Kalager et al., 2010; Morrell et al., 2017; Moss, 1999; Olsen et 
al., 2005; Olsen et al., 2013; Weedon-Fekjær et al., 2014). In women aged 70-74 years 
old who attended a mammography screening, a substantial reduction in mortality 
was reported in several incidence-based mortality (IBM) studies (Coldman et al., 
2014; Jonsson et al., 2003; van Dijck et al., 1997). Also, as compared to women 
screened at ages 50-69, screening mammography performance such as sensitivity, 
positive predictive value and, specificity, increased in older women aged 70-79 
(Sinclair et al., 2011). In contrast, the effectiveness of mammography screening in 
women aged 40-49 was not well evidenced in terms of a reduction in risk of death 
(Elmore et al., 2005; Nelson et al., 2016; Norman et al., 2007; Roder et al., 2008; van 
Schoor et al., 2010).  
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2.2.1.1 Benefits of screening  
The effectiveness of mammography screening can also be measured in terms of a 
reduction in the incidence of advanced breast cancers and its impact on breast cancer 
mortality. Results from randomized trials compared the risk of advanced breast 
cancer between the intervention and control arms and also, the subsequent effect on 
breast cancer mortality (Andersson et al., 1988; Autier et al., 2009; Bjurstam et al., 
2003; IARC, 2016; Miller et al., 1992a; Miller et al., 1992b; Moss et al., 2005; Shapiro, 
1997; Tabár et al., 1992; Tabár et al., 2015). A review study by Tabár et al. (2015) 
showed a substantial and significant effect on breast cancer mortality when the 
cancer was detected at an early stage in the service screening programme (Autier et 
al., 2009; Tabár et al., 2015). The reduction in incidence of advanced disease is also 
associated with a reduction in the risk of greater treatment morbidity and better 
quality of life. Monitoring advanced breast cancer incidence also provides an 
accurate and early indication of the subsequent breast cancer mortality (Tabár et al., 
2015).  
2.2.1.2 Harms of screening: false-positives, overdiagnosis and interval cancers 
While evaluating the effectiveness of mammography screening programmes, the 
associated harms are estimated through performance indicators such as false-positive 
results, overdiagnosis and interval cancers. The occurrence of false-positive results 
varies across the screening programmes due to variation in recall or further 
assessment policies, with and also due to a difference in performance and training of 
the interpreting radiologists (Perry et al., 2006; Hofvind et al., 2012; Myers et al., 
2015; Seely et al., 2018). A pooled estimate of the occurrence of false-positive results 
in mammography screening in Europe reported an approximately 20% cumulative 
risk in the screening of middle-aged and older women (between 50 and 70 years of 
age) after 10 screens (Hofvind et al., 2012). A review study on false-positive results 
in United States reported 31% cumulative risk after 20 years of biennial screening 
(Loberg et al., 2015).    
The term ‘overdiagnosis’ is defined as the detection of breast cancer by screening 
that would never have presented clinically during the woman’s lifetime. 
Overdiagnosed cases of breast cancers are quantified by comparing observed and 
expected cumulative incidence of breast cancer which extends from the beginning 
of screening in screened cohort until several years after screening has ended; that is, 
when the lead time of cancers diagnosed as a result of screening has elapsed (Puliti 
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et al., 2012a). Several studies conducted in Europe and Canada have tried to quantify 
overdiagnosis of breast cancer, but estimates vary widely between earlier randomized 
trial results and recent service screening studies (Gatzsche et al., 2009; Miller et al., 
2002; Moss et al., 2005; Paci et al., 2005; Welch et al., 2010; Zackrisson et al., 2006). 
The estimates from the trials are subject to bias because of shorter follow-up time 
and chances of or access to mammography outside of the trial. The optimal estimate 
can be drawn from the service screening programme either following 10 years after 
the last screen (Duffy et al., 2013) or modelling the lead-time. The estimates range 
from 1%-10% (Puliti et al., 2012b). This also depends on access to mammography 
outside of the programme. Also, the technological advancement and continuous 
development in the practice of screening have modified the risk of overdiagnosis in 
service screening programmes, and thus the estimates differ from those reported by 
randomized trials conducted over 25 years ago. A review of the European 
observational studies (13 primary studies in seven European countries) evaluating 
the overdiagnosis of breast cancer in service screening programmes analysed by 
Puliti et al. (2012) suggested a relatively low estimate of overdiagnosis ranging from 
1% to 10% (Puliti et al., 2012a). In Finland, less than 10% of breast cancer cases are 
overdiagnosed (Heinävaara et al., 2014). However, studies might be subject to 
potential biases that may affect the actual estimates, depending on whether or not 
the estimates are adjusted for the lead-time bias as well as the difference in the 
statistical adjustment for lead time. The variation in the overdiagnosis estimates 
between studies can be explained by the difference in the definition of the population 
at risk (de Gelder et al., 2011), by the differences in the screening policies and uptake 
between programmes (Olsen et al., 2006; Waller et al., 2007),  the screening age 
range, the difference in screening interval and recall practice in various programmes 
and the length of the screening period considered while estimating overdiagnosis 
(Olsen et al., 2006; Paci et al., 2006; Puliti et al., 2009).  
Interval breast cancers inversely affects the effectiveness of the mammography 
screening programme. The interval cancer rates have been assessed in earlier 
randomized studies and also in established service screening programmes. Within a 
single programme, the proportion of interval cancers varies largely between the first 
and second year (from 15%–60% respectively) after the screening mammography 
(Bucchi et al., 2008; Fracheboud et al., 1999; Renart-Vicens et al., 2014; Tabár et al., 
1992; Weber et al., 2016 ), and also by age at mammography screening with more 
cases diagnosed in younger women (Porter et al., 1999). Findings from a meta-
analysis showed a higher (27%) proportion of interval cancers in service screening 
programmes than that of results from randomized trials (19%) (Jacklyn, et al., 2016). 
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A greater variation in the proportion of interval cancers exists between various 
screening programmes, mainly because of a difference in the definition, 
identification and quantification/categorization of interval cancers (Jacklyn et al., 
2016; Bulliard et al., 2006; Lekanidi et al., 2017). Further, the completeness of data 
collection and the use of different inclusion and exclusion criteria may limit the 
comparability of interval cancer rates in different populations. 
2.2.2 Further assessment procedure and histological confirmation 
Women invited to attend a screening clinic first undergo mammography. If any 
abnormality is detected or suspected, women are recalled for further assessment. 
Imaging procedures during further assessment may include additional 
mammography or ultrasonography. Additional mammography includes 
complementary images such as magnified spot compression views, or digital breast 
tomosynthesis. The primary invasive procedure is ultrasonography guided core 
needle biopsy. Microcalfications without a tumour are examined with stereotactically 
guided vacuum assisted biopsy. Both of these provide a histological diagnosis of the 
breast lesion. Core biopsies are performed in the screening clinics, and if possibility 
of breast cancer is confirmed, women is informed about the diagnosis and referred 
to hospital. Few screening units that are part of a hospital breast clinic also perform 
vacuum biopsy, but in most cases the woman is referred to hospital. Referral for 
diagnostic surgical biopsy is made in rare cases where core or vacuum biopsy reveals 
a high-risk lesion, or if there is discrepancy between the clinical or radiological 
finding and the needle biopsy histology. The duration of further assessment and 
histological confirmation procedure to confirm the presence or absence of 
malignancy is about one to two months (in Finland) after the mammography-
screening visit (Sarkeala et al., 2014). The proportion of mammography visits recalled 
for further assessment varies by screening programmes or country, ranging from as 
low as <2% in the Netherlands (Otten et al., 2013) to >5% in the UK and up to 
>10% in the USA (Hofvind et al., 2012; Smith-Bindman et al., 2005). The desirable 
standard in accordance to European Guidelines for recall is <5% at the initial 
screening round and <3% for subsequent rounds (Perry et al., 2006). In Finland, 
<3% of mammography visits are recalled and <1% of visits are referred for biopsy 
examination (Hofvind et al., 2012).  
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2.3 Breast cancer symptoms 
The common symptoms and clinical signs of malignant tumours of the breast ranges 
from a painless mass to hard lump, nipple retraction, nipple discharge, localized 
breast skin changes, persistent axillary swelling, to growth of breast (volume) with 
an inflammatory reddish area and eczematous changes in or around the nipple or 
areola (Clinical Radiology, 2013; IARC, 2016; Joensuu et al., 2013). For metastatic 
breast cancer, there can be (in addition various other symptoms), a lump somewhere 
other than in the breast, pain in the back or hip, or neurological symptoms, 
depending on where the disease has spread (Joensuu et al., 2013).  
     A palpable breast lump is the most important symptom of early breast cancer. 
The majority of lumps are associated with benign breast disease (IARC, 2016; 
Mahoney et al., 1982; Ohene-Yeboah et al., 2008; Pradhan et al., 2008; 
Sankaranarayanan et al., 2011). Lumps characterized with a hard consistency and 
persistent with skin or nipple changes, or unilateral nipple discharge are associated 
with advanced breast cancer (Chen et al., 2012; Giess et al., 1998; Mahoney et al., 
1982). Hospital-based studies reported breast cancer detection between 13% and 
25% in women presented with a lump (Mahoney et al., 1982; Ohene-Yeboah et al., 
2008; Pradhan et al., 2008).  
    Changes or asymmetries in the nipple or areola are an important aspect of early 
detection and breast awareness (IARC, 2002). A tumour located deep in the nipple 
is associated with extensive nipple retraction towards the tumour. Malignant nipple 
retraction should be distinguished from the more common inverted nipple that is 
usually bilateral and lasts for years or decades. Nipple discharge may appear in 
various colours. Even unilateral bloody discharge is usually caused by benign 
conditions (Tabár et al., 1983). Breast pain can be unilateral or bilateral, and the 
distribution can be diffuse or focal. The pain can also be cyclical or non-cyclical 
depending on the menstrual cycle (Tkaczuk et al., 2017). Pain is uncommon as the 
only symptom of cancer.  
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2.4 Breast symptoms reported in the mammography screening 
programmes 
Screening and early diagnosis are important components of comprehensive cancer 
control. Population-based screening is meant for the unselected target populations 
(Perry et al., 2006). All eligible women are invited for screening, mainly based on age 
(mostly by mammography or by other techniques, if existing). The focus of early 
cancer diagnosis is on people who have symptoms and signs consistent with cancer 
(WHO, 2017). However, no evidence supports the effectiveness of such a strategy. 
Early diagnosis of breast cancer can be facilitated by clinical breast examinations by 
a radiographer or by quering women about breast symptoms at the mammography-
screening visit. Different screening or diagnostic protocols for symptomatic and 
asymptomatic women, depending upon the programmes, may be used. 
European guidelines on breast cancer screening recommend recording the 
symptoms and to make this information availableto the radiologists at the time of 
the film reading (Perry et al., 2006). The guidelines also mention referral of all 
symptomatic women to the comprehensive breast units; however, no data is 
available about the procedure regarding referral to those breast units. The Norwegian 
screening programme recalls women with clinical symptoms for further assessment 
(Hofvind et al., 2017). About 0.3% of all screening exams were recalled based on the 
clinical symptoms. Of those screen-detected cancers, 1.7% were symptomatic. No 
information is available about the long-term follow-up after a negative screening visit 
with symptoms. The available online protocols from different countries are mainly 
targeted at managing symptoms reported to general practitioners (GPs) at the 
primary health care centres. Thus, these symptoms are handled outside of the 
screening programme.    
The National Health Service Breast Screening Programme (NHSBSP) guidelines 
in the UK recommend radiologists be alerted about the relevant clinical signs or 
symptoms at the time of reading the mammograms (NHS Breast Screening 
Guidance, 2011). In practice, the majority of women with symptoms first consult 
their general practitioners (GPs). Most of these women are managed by GPs, while 
some patients with significant breast symptoms are sent to hospital breast units for 
a specialist opinion or assessments (Clinical Radiology, 2013; Department of Health, 
2010). Similarly, the National Cancer Control Plan-II of Denmark recommends that 
women with a symptom ‘see a doctor’ with the aim to reduce patient delays, doctor 
delays and system delay; and hence improve the cancer patient pathways (CPPs) 
(National Board of Health, 2005). The doctor then decides whether the symptoms 
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need referral or ‘watchful waiting’ for unclear symptoms. In Australia, protocol is 
also based on symptoms reported to the general practitioners (GPs) (Cancer 
Australia, 2017). We could not locate the protocols of other countries with 
population-based screening programmes that have published in English. Although 
not mentioned and/or no publications were found (except from the UK), it is likely 
that most of the symptoms likely to be malignant are referred to the hospital breast 
units and are therefore not included as the part of the screening programme. Thus, 
the symptoms are not subsequently followed-up and, hence not analysed.  
Earlier studies in the UK have discussed the referral of breast symptoms reported 
at mammography-screening visit (Hide et al., 1999; Litherland et al., 2001; Williams 
et al., 2002). Williams et al (2002) studies the relevance of reported symptoms in a 
breast-screening programme in Wales (Williams et al., 2002). They found a ten-fold 
increase in the detection rate in women who reported significant symptoms as 
compared to the overall screening rate. However, in women with symptoms who 
had a normal mammography, the detection rate was no higher than that expected of 
the normal screening population. The Breast Test Wales (BTW) guidelines suggest 
recording significant symptoms or clinically relevant symptoms such as a new lump, 
retraction, nipple discharge, persistent localized pain, skin dimpling and red nipple 
(Breast Test Wales, 1996). Accordingly, Williams’ study concluded that recall should 
be selective based on only the most relevant symptoms when the mammography 
finding is benign. A similar study in Newcastle, UK, suggested a policy of selectively 
recalling women with symptoms who had normal mammograms (Hide et al., 1999). 
The women selected were those who reported significant symptoms developed in 
the past year prior to the screening visit. Litherland et al. (2001) studied 344 women 
with symptoms but normal screening mammograms identified in the West of 
Scotland Breast Screening Programme (Litherland et al., 2001). They found cancers 
in women complaining of eczematous nipple discharge and dense breast patterns 
but not lumps. They suggested further assessment in the earlier symptomatic group, 
irrespective of mammography findings. All of the above-mentioned studies were 
conducted in a small population size had a short follow-up duration.  
In the Finnish mammography screening programme, all women in the target age 
group are invited irrespective of symptom status (Finnish Cancer Registry, 2018a). 
Women presenting with symptoms such as a lump, nipple retraction or nipple 
discharge are also considered within the programme. The complete information is 
reported electronically to the Mass Screening Registry (Mass Screening Registry, 
2018). However, we cannot rule out that some of these symptomatic women are also 
advised to contact the doctor or specialists to seek further clinical management. 
 40 
 
Breast symptoms reported outside of the mammography screening programme, such 
as in primary health care centres and, outpatient clinics or symptoms reported at 
opportunistic mammography, are not systematically collected in Finland. 
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3 AIMS OF THE STUDY 
The study was conducted within the ongoing organised population-based 
mammography-screening programme in Finland. The main research question was to 
find out whether women with breast symptoms when participating to screening have 
differential risks of breast cancer diagnosis, breast cancer mortality and false positive 
results as compared to asymptomatic women. Specific research questions were 
formulated for each sub-study. How strongly do breast symptoms predict the risks 
of breast cancer diagnosis and mortality? How do breast symptoms affect screening 
programme performance indicators? How big is the added risk of false positive 
results if all women with symptoms are recalled? How great is the added value of 
information provided by symptoms in the screening context? How can this novel 
information be best used to improve screening practices?  
We then formulated detailed study objectives to obtain trustworthy answers to 
the above research questions. The specific tasks of the study were therefore to assess:  
1. The mammography screening programme performance indicators, and 
to then compare between visits with and without symptoms.  
2. The cumulative probability of false-positive mammography test results 
and false-positive referrals in screening visits with symptoms as 
compared to visits without symptoms.  
3. The risk of screen-detected and interval breast cancers in women with 
symptoms as compared to those without symptoms.  
4. The mortality outcomes, breast cancer mortality and all-cause mortality, 
and to then compare between visits with and without breast symptoms 
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4 MATERIALS AND METHODS 
4.1 The organized breast cancer screening programme in 
Finland 
An organized population-based mammography screening programme for breast 
cancer was introduced in 1987 (Hakama et al., 1997). Initially, the programme invited 
women aged 50-59, every two years. By 2007, the biennial screening covered the 
whole country and the upper age of invitation was set at 69. According to the 
Government Decree on Screenings (1339/2011), the Finnish municipalities are 
tasked with organizing screening activities. The screening tests and further 
assessments after recall are performed in organized mammography clinics and are 
free of charge for the invitee. Referral for more detailed diagnostic examinations and 
cancer treatment are performed in specialized medical care (central hospitals) at a 
small outpatient fee. All data gathered in the screening process is reported to the 
Mass Screening Registry of the Finnish Cancer Registry (FCR), which is then used 
to monitor and evaluate the quality and effectiveness of the screening programme.  
     All women in the target population defined by age are invited by personally 
addressed letters to take part in screening (Finnish Cancer Registry, 2018a). The 
Population Information System is used to define the target (or eligible) population 
by using birth year. The Population Information System contains basic information 
such as personal identity code, date of birth, and address. The date and place of 
screening is indicated in the invitation with the possibility to change appointment. A 
reminder letter is sent to those who missed the first invitation (non-attenders). At 
the screening clinic, breasts are examined by digital mammography taken from two 
directions, and images are interpreted by two radiologists. Women are notified of 
the screening results by a personal letter. If the mammography is normal, the women 
are invited back after two years for the next screening round. Women with abnormal 
mammography results are recalled for further assessment. The recalled women 
undergo additional mammography, ultrasound or core needle biopsy if needed. 
Women are informed about the confirmation of breast cancer diagnosis and are 
referred to hospital where they are treated (Figure 4). Follow-up after screening is 
complete for all invited, i.e. until death or emigration.  
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Figure 4.  Flow diagram of mammography screening program by symptom status 
The statistics from 2016 show that invitational coverage is close to 100% (altogether 
381,000 women were invited) with an attendance proportion of 83% (BC screening 
report, 2017). Of those screened, about 3% were recalled at the screening unit/clinic, 
0.8% were referred to hospital and 0.7% (about 2000 women) were diagnosed with 
invasive breast cancers or carcinomas in situ. About a third of invasive breast cancers 
and half of in situ carcinomas were diagnosed within the programme. The numbers 
vary between the health care districts due to differences in both the background risk 
and diagnostic criteria.  
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4.2 Mammography screening visits with breast symptoms 
Women visit the screening clinic with a pre-set time and place for mammography. 
Women may present with symptoms or no symptoms at the screening clinic. The 
radiographer asks if the women have any symptoms during the past two months. If 
women say yes, the radiographer examines the breasts. (Finnish Cancer Registry, 
2018a). Any presence of symptoms such as a lump, retraction, or nipple discharge is 
recorded and reported to the Mass Screening Registry (Mass Screening Registry, 
2018), along with data on screening. Collection of information on lump and nipple 
discharge started from the early years of the programme, but collection of retraction 
information started in 1999. In this current thesis, symptoms reported either by the 
women or the radiographer were considered valid symptoms. After that, breasts are 
examined by mammography. Confirmation procedures after abnormal 
mammography are discussed in the previous section. The benign cases with reported 
symptom status are invited to the next regular screening examination. If a symptom 
appears after a normal mammography or before the scheduled invitation, women 
are advised to consult a doctor (Finnish Cancer Registry, 2018b).   
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4.3 Data source and their linkage 
The Mass Screening Register (MSR) of the Finnish Cancer Registry (FCR) receives 
information about all screened women on a routinely basis through the population 
files and screening centres (Mass Screening Registry, 2018). Individual-level data 
using personal identifiers are registered for use on the invitation (date of invitation, 
municipality) and the screening visit (date of visit, age, symptoms history, 
mammography test results). The information also includes any further assessment 
recommendations and results from them, including date and result of histological 
verification. Histologically confirmed tumours are classified according to the TNM 
classification of tumours published by the Union for International Cancer Control 
(UICC) in 2002 (Sobin et al., 2002).   
Pathological laboratories and clinicians notify the Finnish Cancer Registry of all 
cancers (invasive and in situ). Notification of cancers is based on special law and is 
obligatory. The benign lesions are collected by the Screening Units and sent to the 
MSR. The FCR uses data to monitor cancer at the individual and population level, 
produce cancer statistics and reports and provides data for research proposes. 
Coding of the cancer cases is based on the International Classification of Disease for 
Oncology - 3rd-edition (Fritz et al., 2000). The coding of breast cancer is based on 
topography (C50.0 to C50.9) and morphology codes (M8000 to M8999). The registry 
data covers diagnostic details such as date of diagnosis, cancer site, morphology, 
stage and, behaviour, as well as type of primary treatment given (FCR, 2018a). In 
addition, the registry receives/retrieves demographic information from the 
Population Register Centre. Information on death (date of death, cause of death) is 
also reviewed and compiled by the cancer registry from Statistics Finland.  
To obtain reliable and valid information on screening mammography results, 
incident breast carcinomas and possible deaths, women were linked individually 
between different health care registries using the unique personal identifiers 
available. Information on breast symptoms was extracted from the mammography 
screening form retrieved from the Mass Screening Registry (MSR). Screen-detected 
breast cancers (study I) were defined using data from the MSR and the FCR. All 
breast cancer (screen-detected plus interval cancers) information was available from 
the Cancer Registry (studies II-IV) data base. The FCR validates breast cancer deaths 
using information on pathology, clinical notifications and cause of death data. This 
current thesis utilises breast carcinomas diagnosed before (since 1953; study III, IV) 
and after the implementation of the mammography screening programme in 1987.  
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Table 2.  Data source, target population and screening participation 
  Study I Study II Study III Study IV* 
Data source FNBCSP FNBCSP FNBCSP FNBCSP 
Database linkage MSR (2006–2010), FCR 
(2006–2010) 
MSR (1992–2012), FCR 
(1992–2012) 
MSR (1992–2012), FCR 
(1953–2014), CPR 
(1992–2014) 
MSR (1992–2012),                 FCR 
(1953–2015),                     CPR 
(1992–2014),                   Statistics 
Finland (1953–2015) 
Target population Women aged 50–69 
years old 
Women aged 50–69 
years old 
Women aged 50–69 
years old 
Women aged 50–69 years old 
Study period 2006–2010 1992–2012 1992–2014 1992–2015 
Invited visits 1,454,143 2,627,256 4,594,328 4,594,335 
Attended visits (%) 1,241,486 (85.4) 2,283,706 (86.9) 3,958,305 (86.1) 3,958,312 (86.1) 
* Study IV dataset includes total screening visits of the mammography programme 
in the given period  
FNBCSP: Finnish National Breast Cancer Screening Programme; MSR: Mass 
Screening Registry; FCR: Finnish Cancer Registry; CPR: Central Population Registry 
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4.4 Study design and study population by sub-studies 
This current thesis is based on information collected by the Finnish National Breast 
Cancer Screening Programme (FNBCSP). The target population in the sub-studies 
were women aged 50-69 and invited for screening mammography. Studies I and II 
used data provided by the Mass Screening Registry (MSR) and the Finnish Cancer 
Registry (FCR). In addition to these, study III used Central Population Registry 
(CPR) data and study IV used CPR and Statistics Finland data. (Table 2)  
The first sub-study (I) was a cross-sectional study conducted in women who 
attended screening mammography between 2006 and 2010. Altogether, 1,198,410 
screening visits were studied (Table 3). The second study (II) was a historical cohort 
study conducted in women invited to screening mammography for the first time at 
ages 50-51 between 1992 and 2004 and who were followed up with until 2012. In 
total, 2,189,800 visits with and without symptoms were studied.  
The matched cohort studies (III and IV) were conducted in women who attended 
screening mammography between 1992 and 2012. The exposure group (visits in 
women with breast symptoms at a given screening visit) and reference group (visits 
in women with no breast symptoms in the screening history before the index visit) 
were selected independently of the symptom status. Here, the index visit meant any 
screening visit with any given symptom and a respective asymptomatic visit was 
selected for every symptomatic visit based on the matching criteria. Altogether, 
198,622 visits were analysed in study III and 151,956 visits were analysed in study 
IV. 
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Table 3.   Study design, main method and variables by the sub-studies 
  Study I Study II Study III Study IV 
Study design Cross-sectional study   Historical cohort study Matched cohort study Matched cohort study 
Main statistical method Logistic regression Discrete-time hazard regression Cox-proportional hazards 
model 
Cox-proportional 
hazards model 
Main independent 
variables 
Lump Lump Lump Lump 
Retraction Retraction Retraction Retraction 
Secretion Nipple discharge Nipple discharge Nipple discharge 
Scar 
   
Mole 
   
Performance indicators Attendance proportion False-positive test proportion First and subsequent round 
attendance proportion 
First and subsequent 
round attendance 
proportion Recall proportion False-positive referral proportion 
Referral proportion True-positive proportion Positive predictive value Duration between 
symptoms and cancer 
diagnosis Positive predictive value  Test sensitivity 
Sensitivity  Episode sensitivity Duration between 
symptoms and 
mortality Specificity  Specificity 
Cancer detection rate Negative predictive value 
 
Main outcome variables Screen-detected cancers False-positive tests  Screen-detected cancers Screen-detected 
cancers 
 
 
Tumour characteristics (TNM 
classification) 
False-positive referrals  Interval cancers All cause death 
  
True-positive referrals  Deaths due to breast cancer Deaths due to breast 
cancer     
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Table 4.  Definitions used for the study variables required for the performance indicators 
Serial number Variables Definition  
1.  Test positive Screening visit with primary mammography positive (recalled for further assessment or 
diagnostics) 
2.  Test negative Screening visits with negative/normal mammography (i.e. not recalled for further 
assessment nor diagnostics) 
3.  False-positive test Screening visit with positive mammography but negative further assessment or 
histological confirmation (i.e. no breast cancer) 
4.  False-positive referral Screening visit with positive mammography and referral for biopsy/surgery, but negative 
histological confirmation (i.e. no breast cancer diagnosed) 
5.  Episode negative Screening visit with negative mammography (no recall), or positive mammography but 
negative further assessment or negative histological confirmation 
6.  True positive Screening visit with positive mammography and screen-detected breast cancer 
diagnosed in the same visit  
7.  Screen-detected cancer Primary breast cancer diagnosed within 6 months following a positive mammography 
8.  Interval cancer Breast cancer diagnosed in a screened woman before the next screening visit or within 
a period equal to a screening interval after: a negative mammography; a positive 
mammography but negative further assessment (recall negative); positive further 
assessment but date of diagnosis more than 6 months after screening mammography 
9.  Subsequent round screen-detected 
cancer 
A primary breast cancer diagnosed at the subsequent screening visit in a screen 
negative woman at the index visit 
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Table 5.  Definitions of the performance and outcome indicators 
Serial number Variables Definition  
1.  Breast cancer detection rate (Study I) The number of cancer cases detected at screen divided by number of screening visits 
expressed in 1000 or 10000 
2.  Sensitivity of a symptom (Study I) Number of visits with a symptom with malignant cancers, divided by the total number 
of visits with breast cancer  
3.  Positive predictive value (PPV) (Study I) Number of visits with cancer diagnosed in those who had symptoms 
4.  Test sensitivity (mammography) Number of visits with screen detected cancers divided by the sum of screen-detected 
cancers plus interval cancers diagnosed after negative test results (detection method) 
(Hakama, Pokhrel et al. 2015) 
5.  Episode sensitivity Number of visits with breast cancer detected in the full diagnostic process divided by 
all cancers detected over a screening round among attenders 
6.  Positive predictive value of 
mammography (PPV) 
Number of visits with a positive mammography test and diagnosis of cancer divided 
by the number of all test positives 
7.  Negative predictive value of 
mammography (NPV) 
Number of visits with a negative mammography test and no cancer diagnosed divided 
by the number of all test negatives 
8.  Specificity of mammography Number of visits with a negative mammography test and no cancer diagnosed divided 
by the number of all visits with no cancer diagnosed 
9.  Breast cancer incidence  New breast cancers diagnosedafter the first invitation by the programme divided by 
the person-years at risk 
Incidence of fatal breast cancers (Study III): A subcategory of breast cancer incidence 
was formed of those breast cancers from which the women died. Follow up closed at 
the time of cancer incidence   
 
10.  Breast cancer mortality Deaths due to breast cancer diagnosed after the first invitation by the programme 
divided by person-years at risk. Follow up closed at the time of death  
11.  All-cause mortality Deaths due to any cause, including breast cancer deaths after the first invitation in the 
programme divided by person-years at risk 
The above tables, 4 and 5 illustrates the definition of variables used in the studies. 
The variables are defined in the context of the mammography programme 
performance and the output indicators. In study I, we calculated the clinical validity 
parameters of symptoms within a screening episode whereas, in study II and study 
III we analyzed the performance measures of mammography in relation to 
symptoms in a screening round. Thus, the definition of parameters such as 
sensitivity, PPV, NPV differ between the studies.    
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4.5 Matching by background variables (Studies III, IV) 
Visits with three symptom types (lump, retraction and nipple discharge) were 
frequency matched to asymptomatic visits by age at the screening visit (within two 
years), year of invitation (two-year band), number of past screening visits, and 
municipality of invitation. At first, visits with symptoms were aggregated based on 
matching variables. Each symptom stratum was matched to the viable controls 
(reference group or asymptomatic visits) by random sampling as many times as the 
number of visits in each stratum of symptoms by replacement sampling method. 
Hence, a single control had the possibility to be randomly selected to the same 
stratum more than once. Different symptoms were analysed separately, meaning that 
if more than one symptom was reported at a single visit then each symptom was 
analysed separately. The women from the reference group can later be part of the 
exposed group if symptoms are reported at later screening visits. Thus, symptoms 
act as time dependent covariates. In study III, symptoms reported more than once 
in the screening history were aggregated to form the stratum, whereas, in study IV, 
only the first symptomatic visit with at least one of the symptoms was used for 
sampling, meaning that symptoms reported in later screening visits were excluded in 
the exposure group. In both studies, the exposure-to-reference-visits ratio was 1:1 
for lump and retraction and 1:2 for nipple discharge.   
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4.6 Statistical analysis 
In study I, we assessed the association between breast symptoms reported at the 
screening visit and the risk of screen-detected cancer. We also analysed the clinical 
validity parameters of the symptoms. We utilized logistic regression analysis to 
estimate the age-adjusted association (odds ratios with 95% confidence interval) of 
symptoms with the occurrence of breast cancer. Individual and joint exposure to 
symptoms were analysed in all possible combinations. In addition, breast cancer 
detection rate by symptoms status (symptomatic versus asymptomatic) using 
number of cancer cases detected divided by number of screening visits was 
calculated for all possible combination of symptoms. Breast cancer risks were also 
compared among different five-year age groups categorized into four groups as ‘50-
54’, ‘55-59’, ‘60-64’ and ‘65-69’, and reported using odds ratios with 95% confidence 
intervals.  
In study II, the discrete-time hazard model with ݈݋݃݅ݐ൫ܲሺ ௜ܻ௝ሻ൯ ൌ ᇱܺ௜௝ᇱ ߚ was to 
estimate the cumulative risk of breast cancer according to symptom status at screen. 
Here i is the index subjects i=1,…, n and j is the index visits of ith subject j=1,…,Ji. 
The cumulative risk of first outcome event after k rounds of screening is ݍ௞ ൌ ͳ െ
ς ൛ͳ െ ܲሺ ௜ܻ௝ ൌ ͲǢ ௜ܻሺ௝ିଵሻ ൌ Ͳǡ ǥ ǡ ଵܻ ൌ Ͳሻൟ௞௝ୀଵ  (Christiansen et al., 2000). The 
effects of individual symptoms on the false positive and true positive probabilities 
were estimated using generalized linear model (GLM). Approximate Bayesian 
inference (INLA) (Rue, 2015) was used to estimate the 95% confidence intervals.  
In study III, Cox proportional hazards regression was used to compute the age-
adjusted risk of invasive breast cancer, in situ carcinomas, and non-localized cancers 
in women who reported symptoms as compared to those with no reported 
symptoms at screening visit. The risk-ratio estimate with 95% confidence interval 
was used to compute the risk of screen-detected cancers, interval cancers and 
subsequent round screen-detected cancers. We also estimated the cumulative 
incidence of invasive interval cancers separately for test negatives (from the index 
screen to subsequent screening visit) and episode negatives (from the 6-month 
screening episode to the subsequent screening visit). The follow-up time started 
from the index visit on 1 January 1992 – 31 December 2012 and ended at the date 
of emigration or death, diagnosis of cancers or at the end of the follow-up (31 
December 2014) – whichever occurred first. In addition, cumulative probability of 
non-localized interval cancers at 95% confidence interval was also estimated. The 
programme performance characteristics as defined in section 4.4 were evaluated 
using basic statistics.  
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In study IV, the risk of breast cancer incidence and incidence-based mortality 
(IBM) were computed using Cox proportional hazards regression models. We also 
separately analysed breast cancer mortality and all-cause mortality. The hazard ratios 
(HRs) at 95% confidence intervals (CIs) were used to compare the risk between visits 
with and without symptoms. Likewise, incidence rates and mortality rates were 
calculated using person-years of follow-up at five-year bands since the date of visit 
with or without breast symptoms. Incidence rates were calculated as number of 
breast cancers diagnosed divided by the risk time, whereas mortality rates were 
calculated as number of deaths divided by the risk time. The rates and absolute 
difference in breast cancer incidence and mortality were compared between visits 
with and without symptoms, reported per 10,000 person-years of follow-up at 95% 
confidence intervals. In addition, the cumulative hazards of breast cancer incidence, 
breast cancer mortality and all-cause mortality were estimated using years as the 
underlying time units for risk time.  
All statistical analyses in study I were conducted using Stata version 12.0 (STATA 
statistical software, release 12; Stata Corporation, TX). In study II and study III, all 
statistical analyses were performed using R-3.4.0 version. All statistical analyses in 
study IV were conducted using Stata version 14.0 (STATA statistical software, 
release 14; Stata Corporation, TX).   
 54 
 
4.7 Ethical considerations 
Observational studies based on registry-based data are certainly at risk of putting our 
own goals above those of others – especially the study subjects’. Throughout the 
analysis, we have handled highly sensitive and personal data of mammography-
screening participants. When analysing data from the national registries, a personal 
identification number was necessary for the linkage of information between 
registries. After linkage, however, identifiers were replaced by running numbers 
assigned to subjects in all part of the analysis. The researcher has undergone 
mandatory training at the Finnish Cancer Registry on legislation relating to the 
handling of sensitive individual data. In addition, the researcher has taken a 
mandatory university level education in research ethics and proper data management. 
No contact was made between the researcher and individuals, and the study did not 
have any effect on providing health care for the invited or screened.  
Permission to use the anonymized data was received from the National Institute 
for Health and Welfare (THL/736/5.05.00/2014; THL/461/5.05.00/2018) and 
Statistics Finland (TK-53-1258-13). 
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5 RESULTS 
5.1 Symptoms prevalence and performance indicators in the 
screening programme 
Over the years 1992 to 2012, 3, 958, 312 screening visits were made in the Finnish 
mammography programme, with an attendance proportion of 86.1%. Of these, 
51,698 (1.4%) visits were recorded with a lump, 41,326 (1.5%) visits with retraction 
and 9,131 (0.3%) visits with nipple discharge (see Table 6). The proportion of visits 
with a lump decreased with an increase in the age group, from 1.6% in the youngest 
age group of 50-53 to 1.1% in the older age group of 66-69, in visits with retraction, 
a reverse order was observed from 1.1% in age group 50-53 to 2.1% in age group 
66-69. Nipple discharge increased slightly in those of a younger age than of a higher 
age. The proportion of visits with a lump (2.7% versus 1.2%) were higher in the 
earlier years (1992-1997) of the programme than in recent years (2008-2012). The 
opposite was true in the case of retraction and nipple discharge. 
Altogether, 14% of visits with a lump, 9% of visits with nipple discharge and 4% 
of visits with retraction were recalled as compared to less than 3% of visits without 
symptoms (Table 7). Similarly, a higher proportion of visits with all symptom types 
were referred for surgery as compared to those visits without symptoms. The cancer 
detection rate was 30 per 1,000 visits with a lump, 12 per 1,000 visits with a retraction 
and 9 per 1,000 visits with a nipple discharge as compared to about 5 per 1,000 visits 
without symptoms.   
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Table 6.  Symptoms prevalence using the whole dataset of attended visits during 1992-2012 
    Lump     Retraction#     Nipple discharge 
Characteristics   Yes No   Yes No   Yes No 
Number of attended 
visits* 
3958312 51698 (1.41) 3614873 (98.5) 
 
41326 (1.53) 2656405 (98.4) 
 
9131 (0.25) 3676681 (99.7) 
Age at visit 50 to 53 18279 (1.60) 1127523 (98.4) 
 
8596 (1.14) 744762 (98.8) 
 
4001 (0.35) 1150694 (99.6)  
54 to 57 15326 (1.39) 1088271 (98.6) 
 
10956 (1.40) 769685 (98.6) 
 
2564 (0.23) 1113826 (99.7)  
58 to 61 10919 (1.29) 836276 (98.7) 
 
11263 (1.72) 644072 (98.3) 
 
1590 (0.19) 849793 (99.8)  
62 to 65 5349 (1.34) 393994 (98.6) 
 
7197 (2.06) 342167 (97.9) 
 
654 (0.17) 393148 (99.8)  
66 to 69 1825 (1.07) 168809 (98.9) 
 
3314 (2.08) 155719 (97.9) 
 
322 (0.19) 168220 (99.8) 
Period of visit 1992 to 1997 15502 (2.74) 549551 (97.2) 
 
NA NA 
 
1136 (0.21) 527757 (99.7)  
1998 to 2002 7562 (1.0) 745440 (99.0) 
 
3570 (1.02) 346196 (98.9) 
 
1681 (0.22) 768628 (99.7)  
2003 to 2007 11936 (1.19) 994557 (98.8) 
 
13083 (1.30) 992935 (98.7) 
 
2880 (0.27) 1050603 (99.7)  
2008 to 2012 16581 (1.24) 1316877 (98.7) 
 
24491 (1.84) 1308967 (98.1) 
 
3412 (0.26) 1321164 (99.7) 
*number of attended visits in each symptom category excludes the missing visits; # 
information collected since 1999 
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Table 7.  Programme performance indicators by symptom status using the whole dataset of 
attended visits during 1992-2012 
    Lump     Retraction#     Nipple discharge 
Characteristics   Yes No   Yes No   Yes No 
Recall proportion 
(%) 
Yes (test-positives) 7263 (14.1) 92040 (2.55) 
 
1649 (3.99) 69493 (2.62) 
 
817 (8.95) 98901 (2.69) 
 
No (test-negatives) 44428 (85.9) 3522466 (97.4) 
 
39677 (96.0) 2586538 (97.4) 
 
8314 (91.0) 3577409 (97.3) 
Referral proportion 
(%) 
Yes (episode positives) 1993 (5.21) 21336 (1.0) 
 
604 (2.69) 17104 (1.42) 
 
211 (3.31) 23336 (1.06) 
 
No (episode negatives) 36247 (94.7) 2111769 (99.0) 
 
21868 (97.3) 1188341 (98.5) 
 
6172 (96.6) 2174073 (98.9) 
True positives or 
cancer detection 
rate (per 1000 
visits) 
  1546 (29.9) 15560 (4.3)   505 (12.2) 13073 (4.92)   82 (8.98) 17221 (4.68) 
#information collected since 1999 
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5.2 Clinical validity of symptom and screening mammography 
quality measures (Studies I, III) 
The sensitivity to detect cancer in women with a lump (8%) was higher than those 
with retraction (4%) or nipple discharge (0.7%). Similarly, the PPV was higher for a 
lump than for retraction and nipple discharge. The specificities of all symptom types 
were about 99% (Table 8).  
The mammography test sensitivity was higher for visits with a lump and 
retraction but not for visits with a nipple discharge as compared to visits without the 
respective symptom type (Table 9). The specificity of the mammography test was 
higher for visits without symptoms as compared to visits with a lump (98% versus 
88%), not so different for visits with a retraction (98% versus 97%) and lower for 
visits with nipple discharge (98% versus 92%). Similarly, the PPVs were higher for 
visits with a lump and visits with retraction but not for visits with nipple discharge 
as compared to visits without the respective symptoms.  
Table 8.  Clinical validity of symptoms with reference to cancer detection in the mammography 
screening programme 
Symptoms Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) 
Lump 7.62 (7.04 - 8.32) 98.7 (98.7 - 98.8) 3.19 (2.92 - 3.48) 
Retraction 3.71 (3.27 - 4.20) 98.3 (98.2 - 98.3) 1.16 (1.02 - 1.32) 
Nipple discharge 0.66 (0.48 - 0.89) 99.7 (99.7 - 99.7) 1.08 (0.79 - 1.47) 
Any symptoms 35.5 (34.3 - 36.6) 75.2 (75.1 - 75.3) 0.78 (0.74 - 0.81) 
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Table 9.  Performance quality measures of screening mammography with reference to cancer 
detection by symptom status 
Symptoms   Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) 
Lump Yes 81.9 (80.1 to 83.7) 88.3 (88.0 to 88.6) 19.9 (19.4 to 20.4)  
No 64.4 (58.4 to 70.2) 97.5 (97.4 to 97.6) 12.1 (11.1 to 13.3) 
Retraction Yes 76.9 (73.4 to 80.3) 97.1 (96.9 to 97.2) 28.1 (26.7 to 29.6)  
No 66.7 (60.9 to 72.1) 97.8 (97.7 to 98.0) 17.9 (16.4 to 19.5) 
Nipple discharge Yes 62.3 (52.3 to 71.5) 91.7 (91.1 to 92.2) 8.12 (6.98 to 9.42) 
No 70.3 (61.2 to 78.4) 97.5 (97.3 to 97.7) 15.5 (13.7 to 17.6) 
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5.3 Probabilities of false-positive results by symptom type 
(Study II) 
In total, 12% of visits with a lump, 2.5% of visits with a retraction, and 8% of visits 
with a nipple discharge had false-positive mammography test results (Table 10). On 
the other hand, about 2% of visits without symptoms had false-positive 
mammography. Additionally, 0.8% of visits with a lump, 0.2% of visits with 
retraction and 1.6% of visits with nipple discharge had false-positive findings during 
further assessment (referral for surgery) as compared to 0.15% of visits without the 
respective symptoms.  
In the same way, the cumulative risk of false-positive tests after 10 screening visits 
was higher for visits with a lump (45%), retraction (25%) or nipple discharge (35%) 
as compared to visits without the respective symptoms. Likewise, the cumulative risk 
of a false-positive referral after 10 screening visits was higher for visits with a lump, 
retraction or nipple discharge as compared to those without the respective 
symptoms.  
Table 10.  Probabilities of false-positive test and false positive referral after 10 screening visits 
Symptoms Screening visits False-positive test 
 
False-positive referral 
Number (%) Cumulative 
probability (%) 
  Number (%) Cumulative 
probability (%) 
Lump Yes 26145 3140 (12.0) 45.2 
 
212 (0.81) 3.32  
No 2114103 42527 (2.01) 17.2 
 
3114 (0.15) 1.46 
Retraction Yes 26653 668 (2.51) 24.6 
 
46 (0.17) 2.61  
No 1652257 30460 (1.84) 18.1 
 
2026 (0.12) 2.04 
Nipple 
discharge 
Yes 5325 423 (7.94) 34.7 
 
85 (1.60) 7.89 
No 2184475 45873 (2.1) 18.1   3306 (0.15) 1.46 
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5.4 Risk of screen-detected breast cancers in symptomatic 
versus asymptomatic women (Studies I, III) 
Table 11 shows the rates (per 1,000 visits) and risk (risk ratios at 95% CI) of screen-
detected breast carcinomas in women who reported symptoms as compared to those 
without symptoms at screening visit (study III). The detection rates of invasive breast 
cancer were elevated in women who reported a lump (28 versus 3 per 1000 visits), a 
retraction (11 versus 4 per 1,000 visits) or nipple discharge (7 versus 4 per 1000 visits) 
as compared to respective asymptomatic visits. Similarly, the non-localized invasive 
cancer detection rates were elevated for all symptom types than that of respective 
asymptomatic visits. The in situ detection rate was higher for visits with a lump but 
only slightly higher for visits with retraction or nipple discharge.  
In relative terms, the age-adjusted risk of screen-detected invasive breast cancer 
in women who reported a lump was 8-fold (HR, 7.1 to 9.7) compared to those 
without a lump (Table 11). The risk was 2.4-fold (HR, 2 to 2.8) for retraction and 
1.7-fold (HR, 1.2 to 2.3) for nipple discharge as compared to those without the 
respective symptoms. Similarly, the risk of non-localized invasive breast cancer 
increased for all symptom types. In addition, the risk of in situ carcinoma was 
elevated in those who reported a lump (HR 1.6, 95% CI 1.1 to 2.4) but not for those 
who reported a retraction or a nipple discharge as compared to the respective 
asymptomatic visits.   
Table 12 illustrates the joint effect of different symptoms on the risk of breast 
cancer (study I). In screening visits where both lump and retraction were reported, 
the risk of breast cancer was 22 times higher (95% CI 16.5 to 30.8) than those 
without symptoms. Similarly, the risk was 5.4 times higher (95% CI 4.3 to 6.7) in 
screening visits with a lump and scar and 2.3 times higher (95% CI 1.7 to 3.1) in 
visits with a retraction and scar as compared to those without the respective 
symptoms. We did not see an additional increase in the risk of breast cancer when 
scar was reported together with a lump or retraction in a given visit.  
We also estimated the risk of screen-detected breast cancer by age groups (five-
year interval) as reported in study I. In women who reported a lump or retraction, 
the risk of breast cancer was higher across all age groups. For nipple discharge, the 
risk was increased only in the older age groups, i.e., 60-69 years old (Figure 5). We 
did not find a prominent increase in the risk with increased age in women who 
reported symptoms.   
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Table 11.  Cases (proportion/1000 visits) and age-adjusted risk (risk ratios) of screen-detected 
cancers in those who reported symptoms as compared to those without symptoms at screen 
Symptom Cancer outcomes With symptoms 
 
Without symptoms Age-adjusted hazards ratio (95% CI)  
Cases per 1000 visits 
(%) 
  Cases per 1000 visits 
(%) 
Lump Invasive 1440 (28.1) 
 
174 (3.39) 8.26 (7.1 to 9.70)  
In situ 61 (1.19) 
 
38 (0.74) 1.61 (1.08 to 2.43)  
Non-localized 693 (13.5) 
 
57 (1.11) 12.0 (9.22 to 16.0) 
Retraction Invasive 461 (11.3) 
 
192 (4.69) 2.39 (2.02 to 2.84)  
In situ 35 (0.86) 
 
31 (0.76) 1.13 (0.70 to 1.84)  
Non-localized 230 (5.62) 
 
61 (1.49) 3.47 (2.62 to 4.66) 
Nipple 
discharge 
Invasive 66 (7.27) 
 
83 (4.57) 1.66 (1.19 to 2.31) 
In situ 15 (1.65) 
 
16 (0.88) 1.87 (0.92 to 3.81) 
  Non-localized 25 (2.75)   27 (1.49) 1.85 (1.05 to 3.22) 
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Table 12.  Odds ratios (ORs) of breast cancer with 95% confidence intervals (CI) for joint 
exposure to symptoms 
Symptoms Screened women Cancer cases (%) Age-adjusted OR (95% CI) 
Lump | Retraction 36036 695 (1.93) 
 
No | No 1162374 5829 (0.50) Reference 
No | Yes 20449 198 (0.97) 1.94 (1.68 to 2.24) 
Yes | No 15156 453 (2.99) 6.15 (5.55 to 6.74) 
Yes | Yes 431 44 (10.2) 22.6 (16.5 to 30.8) 
Lump | Scar 152515 1380 (0.90) 
 
No | No 1045895 5144 (0.49) Reference 
No | Yes 136928 883 (0.64) 1.31 (1.22 to 1.41) 
Yes | No 12378 414 (3.34) 7.0 (6.32 to 7.75) 
Yes | Yes 3209 83 (2.59) 5.37 (4.31 to 6.69) 
Retraction | Scar 157121 1162 (0.74) 
 
No | No 1041289 5362 (0.51) Reference 
No | Yes 136241 920 (0.68) 1.31 (1.22 to 1.41) 
Yes | No 16984 196 (1.15) 2.26 (1.95 to 2.60) 
Yes | Yes 3896 46 (1.18) 2.31 (1.72 to 3.09) 
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Figure 5.  Risk (OR, 95% CI) of breast cancer among women who reported symptoms by age-
groups, respectively as ‘50-54’, ‘55-59’, ‘60-64’ and ‘65-69’   
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5.5 Risk of interval breast cancers in symptomatic versus 
asymptomatic women (Study III) 
The rates of interval breast cancers (invasive and in situ) were raised after the 
screening visits with a lump (422 versus 112 cases per 1000 visits), visits with 
retraction (161 versus 107 cases per 1000 visits) or visits with nipple discharge (61 
versus 45 cases per 1000 visits) as compared to visits without respective symptoms 
(Table 13). For nipple discharge, two asymptomatic visits were selected for each visit 
(see materials and methods; section 4.6). The age-adjusted risk of invasive interval 
breast cancer was 4 times (95% CI 3 to 4.7) higher in visits with a lump, 1.5 times 
(95% CI 1.2 to 2) higher in visits with retraction and 2.5 times (95% CI 1.7 to 3.8) 
higher for nipple discharge as compared to respective asymptomatic visits. Similarly, 
the risk of non-localized interval cancers was increased for all-three symptom types, 
whereas the risk of in situ interval carcinomas was higher for visits with a lump (HR 
3.9, 95% CI 1.9 to 8.6) or nipple discharge (HR 4, 95% CI 1.3 to 15) but not for 
visits with retraction (HR 1.2, 95% CI 0.4 to 3.6).  
We also analysed the risk of breast cancer diagnosed at the subsequent screening 
visit after the index visit with or without symptoms (Table 13). The risk of 
subsequent round invasive screen-detected cancer was higher in those who reported 
a lump (HR 1.7, 95% CI 1.4 to 2.1) but not for visits with a retraction (HR 1.1, 95% 
CI 0.9 to 1.4) or nipple discharge (HR 1, 95% CI 0.6 to 1.5) as compared to visits 
without the respective symptoms. Notably, the risk of in situ carcinomas in the 
subsequent round was increased for visits with nipple discharge (two-fold) and for 
visits with a lump (1.5-fold) but not for visits with a retraction.   
The cumulative incidence of interval breast cancers was estimated separately for 
test positives and negatives with or without symptoms (see Figures 6a-6c). In test 
negative visits (no recall), the incidence of interval breast cancer in those with a lump 
increased rather rapidly after the first month as compared to visits without a lump. 
While considering the cumulative incidence of breast cancer among the 
asymptomatic visits after 23 months (full follow-up over one round) as a reference, 
the same cumulative incidence was reached within 6 months after visits with a lump 
and in 12 months after visits with nipple discharge. In addition, the non-localized 
breast cancers were diagnosed rather rapidly after the screening visits if a lump was 
reported as compared to those without a lump. On the other hand, in women who 
reported a lump and were recalled for further assessment, the difference in the 
probability of interval breast cancer was clearly visible in the graph soon after the 
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negative further assessment as compared to those visits without lump but not likely 
for visits with a retraction or nipple discharge.   
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Figure 6.  (a-c): Cumulative incidence of invasive (per 1000): a) recalled ICs; b) not recalled ICs; c) 
non-localized ICs 
Note: The confidence intervals lines for cumulative incidence are indicated by light 
dotted lines in symptomatic and asymptomatic groups 
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5.6 Breast cancer mortality and all-cause mortality in 
symptomatic versus asymptomatic women (Study IV) 
In Table 14, we report the breast cancer mortality and all-cause mortality rates and 
risk ratios by symptom types in the screened women after the first invitation by the 
programme and followed-up with over a period of 24 years. We found an increase 
in breast cancer mortality rates in women who reported a lump (5.3 per 10,000 
person-years, 95% CI 4.5 to 6.2) or retraction (2.9 per 10,000 person-years, 95% CI 
2 to 3.8) but not nipple discharge (0.8 per 10000 person-years, 95% CI minus 0.5 to 
2) as compared to respective women with asymptomatic visits. The breast cancer 
mortality rates were very high within the first five-years after a screening visit with a 
lump as compared to no lump (78 versus 8 deaths per 10,000 person-years) or 
retraction (19 versus four deaths per 10,000 person-years) (see study IV). Similarly, 
the difference in all-cause mortality rates were prominent after visits with a lump or 
retraction but not after visit with a nipple discharge.    
In relative terms, breast cancer mortality was increased for visits with a lump (3-
fold) or retraction (3.9-fold) but not for visits with nipple discharge. However, all-
cause mortality rate ratio was elevated for all symptom types as compared to the 
respective asymptomatic visits. We also found extra all-cause death cases in women 
with lower socio-economic class and reported a lump than those in higher class and 
without lump, respectively. As shown in figure 7 (Figures 7a-7b), the incidence of 
breast cancer mortality in screening visits with a lump or retraction increased rather 
rapidly. A similar level of risk was reach in half of the follow-up time in those with 
symptoms as compared to the risk in the respective asymptomatic visits after 24 
years of follow-up (Figure 6). The cumulative hazards curve for visits with a lump 
or retraction followed a similar pattern of breast cancer mortality and all-cause 
mortality but no similarity was observed for visits with nipple discharge. 
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Figure 7 (a-b): Cumulative risk of (a) breast cancer mortality and (b) all-cause mortality per 10000 
person-years of follow up 
Note: The confidence intervals lines for cumulative risk are indicated by light dotted 
lines in symptomatic and asymptomatic groups  
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6 DISCUSSION 
6.1 Screening test and performance indicators in relation to 
symptom status 
The results reported in this study (sub-studies II, III, IV) are based on the complete 
follow-up of the screening aged women from the early years of the implementation 
of the mammography-screening programme until the most recent year, 2015. The 
screening attendance proportion (86%) reported in the study is among the highest 
of the existing mammography screening programmes, and it had near 100% 
coverage. A recent annual review of the Finnish breast cancer-screening programme 
reported a slight decline in the attendance proportion to 83% (Finnish Cancer 
Registry, 2017). We found that about 3% of women reported breast symptoms at 
the screening visit, which is lower than that reported by other studies. However, 
most studies are based on the diagnostic mammographic exams (Barlow et al., 2002; 
Lumachi et al., 2002; Seltzer, 1992; Sterns, 1992) or premenopausal women (Aiello 
et al., 2004) for whom symptom prevalence is high. 
 We found that 14% of screening visits with a lump were recalled for further 
assessment compared with only 3% of those without a lump. In addition, a higher 
proportion of visits with a retraction or nipple discharge were recalled. In the 
Norwegian screening programme, only 0.3% of visits based on clinical symptoms, 
of all those screened were recalled (Hofvind et al., 2017). The usual practice in many 
screening programmes is to refer women with symptoms to general practitioners or 
specialized breast clinics irrespective of the mammography findings (Clinical 
Radiology, 2013; Department of Health, 2010); Cancer Australia, 2017). About 3% 
of screening visits with a lump and 1% of visits with a retraction or nipple discharge 
were diagnosed as cancer as compared to about 0.5% in asymptomatic visits. Studies 
on diagnostic examinations reported higher breast cancer diagnosed among 
symptomatic women than that reported in our findings (Aiello et al., 2004; Lumachi 
et al., 2002; Seltzer, 1992; Sterns, 1992). As mentioned earlier, our study involved 
screening-age women who come for invitation-based mammography screening 
examination, whereas other studies (Sterns, 1992) were conducted among 
symptomatic women outside the screening programme. Thus, the variation in the 
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screening strategies, information collected on symptoms, age of the women or 
diagnostic examination instead of screening make these findings not directly 
comparable. A study conducted in the USA based on samples extracted from the 
medical chart record of screening and clinical breast examinations reported that 10% 
of women had symptoms; of those, 2% had cancer diagnosed (Ryerson et al., 2015). 
A study in the UK by Williams et al. (2002) found a higher proportion (45%) of 
cancers diagnosed in women presenting with symptoms and recalled for further 
assessment than our study (Williams et al., 2002). However, the recall decision was 
based on the mammography abnormality findings, and only women labelled as 
having significant breast symptoms as defined by Breast Test Wales (BSW) 
guidelines (Breast Test Wales, 1996) were recalled. Similar studies conducted in the 
UK are based on a small population of screening aged women and, thus the 
proportion of cancers diagnosed was low (Hide et al., 1999; Litherland et al., 2001; 
Williams et al., 2002).   
In the first study (I), the positive predictive value (PPV) of a lump was 3.2%, 
which is higher than the PPV of 1%, as reported by other studies (Fenton et al., 
2005; Mittra et al., 2010; Sankaranarayanan et al., 2011), mainly based on clinical 
breast examinations, but few hospital-based studies (Harvey et al., 2003; Kerlikowske 
et al., 1996; Mahoney et al., 1982; Ohene-Yeboah et al., 2008; Pradhan et al., 2008) 
reported higher PPV (between 13% and 15%) than our study. In addition, the 
sensitivity of symptom was low, which can be explained by the difference in the 
screening population - who normally undergo several rounds of screening in the 
programme and have access to mammography outside the programme - and the 
magnitude of diagnostic activities than those reported in the above-mentioned 
studies. The mammography test sensitivity and PPV were elevated in screening visits 
with a lump or retraction as compared to those without respective symptoms. Our 
sensitivity findings were in line with or higher than the screening estimates in other 
programmes (Perry et al., 2006; Hofvind et al., 2004; Njor et al., 2003; Vitak et al., 
1997; Wang et al., 2001) and also higher than those reported in a pooled analysis 
study in 6 European countries (Tornberg et al., 2010), but we could not find 
estimates based on the symptom status. 
  
 74 
 
6.2 Symptoms associated with breast cancer outcomes 
We found an increased risk of screen-detected breast cancers in screening visits with 
any given symptom types as compared to respective asymptomatic visits (study I, 
III). A study by Aiello et al., based on screening or diagnostic exams reported a more 
than three-fold risk in women who had a lump, but no elevated risk was found for 
visits with a nipple discharge or breast pain (Aiello et al., 2004). A few other studies 
(Brouckaert et al., 2013; Gill et al., 2006) have also reported a higher risk of screen-
detected breast cancer in those who reported a lump, but a lower hazard ratio than 
that reported in our study (study III). However, those studies were limited to many 
factors, such as study design, size, follow-up time and assessment of the possible 
outcome measures of breast cancer.   
The risk of interval breast cancers was also elevated in screening visits with all 
symptom types as compared to asymptomatic visits. We are not aware of other 
studies that have reported interval cancer rates in relation to breast symptoms at 
screening visit. As well, the definition, identification and quantification of interval 
cancers vary largely by screening programmes (Bulliard et al., 2006) or within the 
same screening programmes depending on the sensitivity of the mammography test 
(Day, 1985; Perry et al., 2006; Houssami et al., 2006; Mushlin et al., 1998; 
Vinnicombe et al., 2009), sensitivity of the further assessment procedures (Perry et 
al., 2006; Hakama et al., 2007; Taylor et al., 2002; Taylor et al., 2004; Tornberg et al., 
2010) or programme sensitivity (Anttila et al., 2002; Zorzi et al., 2010). 
We found relatively higher all-cause mortality rates than breast cancer mortality 
rates between symptomatic and asymptomatic visits and substantial difference in the 
rates between these groups throughout the follow-up period. In addition, both the 
all-cause mortality and breast cancer mortality within five years of the screening visit, 
especially with a lump, were astonishingly higher than those without lump. In 
absolute terms, in every 10,000 person-years of follow-up with a lump at screen, 180 
women died from breast cancer as compared to 70 women without a lump, and 315 
cases of all-cause deaths in women with a lump as compared to 160 deaths in women 
without lump, respectively, after 24 years of follow-up. The difference between the 
symptomatic and asymptomatic group in mortality was not clearly related to specific 
causes of death other than breast cancer. We found a surplus number of death cases 
women of in lower socio-economic status and surplus deaths in those who had a 
lump. Having a lower socio-economic status might partially affect the findings on 
symptoms, therefore also affecting mortalities from any cause. Nevertheless, the 
socio-economic status of the whole cohort was unknown in our study. No other 
 75 
studies have reported the difference in mortality between these sub-groups. 
Furthermore, systematic review conducted in Europe has reported that a lower 
socio-economic status is linked to several factors, such as lower screening 
attendance, delayed diagnosis and, larger tumour, which all pose an increased risk of 
mortality in this group (Feinglass et al., 2015; Kaffashian et al., 2003; Lundqvist et 
al., 2016; Rawshani et al., 2016; Yu, 2009). 
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6.3 Strengths and limitations 
The results represented in this thesis were obtained from the organised Finnish 
National Breast Cancer Screening Programme (FNBCSP), which covers nearly 
100% of the target age population (50-69 years). The unique personal identifier 
allows accurate linkage of data available at the comprehensive national registers. The 
collection of information on screening invitations, mammography tests, further 
assessments by the mass screening registry, and cancer outcomes for the whole 
population by the cancer registry provides several major advantages to conducting 
research in the Finnish programme. The collection of information on breast 
symptoms reported during the mammography screening visits allows for studying 
the impact of symptoms not yet available or published in any other programme. 
No prior studies have estimated the risk of breast cancer, false-positive test 
findings and cancer mortality in relation to breast symptoms in a prospective 
manner. Follow-ups were done for a maximum of 24 years and a maximum of 10 
screening visits after screening visits with or without symptoms. The study used 
screening history and symptom history information of all screening-age women in 
Finland who had biennial screening mammography, and followed up for further 
assessments until cancer diagnosis and death. The main benefit of using data on 
breast symptoms reported within the screening programme is that one can study 
cancer incidence and deaths from breast cancer in symptomatic women as compared 
to non-symptomatic. Additionally, harms in terms of false-positive findings were 
assessed for the first time in this study. 
One key strength of this study is that follow-ups were performed until the date 
of the last screening visit or the diagnosis of cancer or death, whichever came earliest. 
The individual-level data allowed us to extract screening history information of every 
woman who presented with symptoms or who did not have symptoms. This is 
unique in the Finnish programme. 
     In studies III and IV, we made the symptomatic and asymptomatic group 
more comparable by matching with the background variables at any given period of 
the screening visits. This minimized the bias in the risk estimates by the confounders. 
As we used the full screening cohort, the study power was sufficient to compute the 
difference in risk and rates for symptomatic and asymptomatic visits. Because not all 
symptoms are equally sensitive, each symptom was analysed independently thus it 
was possible to analyse the risk of cancer and mortality for every individual symptom. 
It is important to ensure that women with symptoms have equal opportunity to 
participate in the screening programme as those without symptoms. This means that 
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the screening effectiveness is to be evaluated based on all eligible women invited, 
regardless of any personal or risk history. Such evaluation reflects the actual scenario 
in the existing screening-age population. However, this study also highlights the 
importance of differential follow-up assessment of women who have a differential 
risk. 
The definitions of the programme process and outcome indicators used in these 
studies adhere to the WHO-IARC and EU guidelines, as well as other international 
guidelines on breast cancer screening and diagnosis (Perry et al., 2006; IARC, 2016). 
Thus, future studies conducted in other screening programmes could utilize our 
study methods and findings. Furthermore, the findings of our studies could be 
applied to other existing and new programmes to improve the performance and 
effectiveness of screening mammography.   
The studies contained several limitations. 
One of the potential limitations is the collection of symptoms information. The 
collection was based on the women’s self-reporting and by radiographers at the 
screening visits. The radiographers’ physical inspection of the breast is likely to be 
less comprehensive than a full clinical examination. Information on symptoms is 
mainly collected in order to support the interpretation of the mammograms. 
However, in most of the cases, the presence of symptoms is confirmed by having 
the radiographer examine the breasts before the mammography is performed. This 
supports that the collected symptom information is valid, albeit not perfect. 
Women with symptoms were possibly more likely to attend mammography 
screening than asymptomatic women leading to a self-selection bias. However, about 
84% of all invited women participate in mammography screening in the Finnish 
programme, which is the highest among any existing mammography screening 
programme. In addition, most of the women who attended were asymptomatic 
(about 97%), and thus the attendance bias caused by symptoms is likely to be small. 
Another issue is the recall bias. We do not know about any possible delay in 
presentation of symptoms: whether women waited for their first invitation (i.e., at 
age 50 years) or a subsequent screening invitation. The symptom information is 
based on the women’s reporting of symptoms in the past two to six months and the 
examination by the radiographer at the screening visit. Women were more likely to 
remember any recent abnormalities in their breasts, and thus the recall bias is not 
likely to be of higher importance. 
An important limitation is the inability to address the potential confounding 
effect of important risk factors that do not exist in the database. Thus, effect 
adjustment by factors such as family history, breast density, hormone use and socio-
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economic status, which are known to influence breast cancer risk, was not possible 
in this study (Anderson et al., 2014; Barnard et al., 2015; Collaborative Group on 
Hormonal Factors in Breast Cancer, 2001; IARC, 2012a; IARC, 2012b). 
The estimate of sensitivity, specificity and positive predictive value (PPV) of 
diagnosing breast cancer cases with symptoms in study I was limited to those women 
who attended mammography screening. Cancer cases detected outside of screening 
were excluded. The low sensitivity of symptoms in this study indicate that a 
mammography screening programme is still justified. 
Study III was sensitive to lead-time bias and overdiagnosis because we used 
detection method instead of the use of background incidence of breast cancer to 
estimate the interval cancer rate in the absence of screening. However, it was not 
possible to find a comparable non-screened group as the Finnish screening 
programme has a high coverage (almost 100%) and attendance rate (about 84%). As 
well, there was no possibility to estimate the background incidence of breast cancer 
in women with symptoms. In addition, the positive predictive value (PPV) of 
mammography did not differ between the symptomatic and asymptomatic groups 
between the first and subsequent screening round, and thus the lead time bias due 
to prevalent screenings is negligible. Furthermore, our estimates of incidence rates 
and hazard ratios were based on the analysis of invasive breast cancers and on 
advanced and fatal breast cancers, both of which are less affected by overdiagnosis. 
Nonetheless, the proportion of in situ carcinomas was only 5% in those with 
symptoms. 
In study IV, we analysed the difference in socio-economic statuses between 
symptomatic and asymptomatic women who were diagnosed or died of cancer. In 
women who reported a lump, we observed extra all-cause death cases in lower socio-
economic class than in upper classes and also an extra  number of deaths as 
compared to those without a lump. However, the socio-economic status of the 
whole cohort was unknown; thus, the proportion of breast cancer deaths or all-cause 
deaths in those with or without symptoms might differ from the study estimates. 
The higher all-cause mortality rates than breast cancer mortality rates, and also the 
difference in the rates between symptomatic and asymptomatic group throughout 
the follow-up period might be explained partially by the difference in socio-
economic status.  
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6.4 Clinical and public health implications 
The breast symptoms in this study provide new evidence on the benefits and harms 
of screening mammography. The study provides novel data on the risk of breast 
cancer (screen-detected and interval cancers) and mortality from breast cancer in 
relation to breast symptoms. The symptom status should not be restricted to support 
the interpretation of the mammography, but needs to be extended to improve 
programme performance. Our findings can be applied to various steps in the 
programme, from the initial design to performance assessment and up to the 
evaluation of outcomes. 
The design of the Finnish mammography-screening programme, where 
invitations include all women of a certain age (including those with symptoms) 
differs substantially from many other programmes. Women presenting with 
symptoms are still considered part of the screening programme in Finland, whereas 
many screening programmes refer symptomatic women directly to hospitals or 
special breast clinics. However, clinical check-up may still miss cancers and may not 
offer optimal opportunities for systematic follow-up as the screening programme. 
An important consequence of excluding women with symptoms is the decreased 
validity of programme evaluation, since a considerable proportion of women with 
symptoms are left out. Based on our findings, this means that a prominent number 
of cancer cases are missed. In addition, assessing symptomatic women outside the 
programme may demand additional resources (Walker et al., 2014). 
The next step is an appropriate inquiry into symptoms information by the 
radiologists or nurses with additional information, such as duration of symptoms 
and severity of pain (Walker et al., 2014) or other possible findings based on 
palpation (Breast Test Wales, 1996; Hide et al., 1999; Litherland et al., 2001). The 
findings in study III showed a higher screening test and episode sensitivity in women 
presenting with symptoms compared to asymptomatic women. Particularly, of 
women who reported a lump, loss occurred in the episode sensitivity in the further 
assessment, meaning that all women presenting with symptoms were not recalled. 
On the other hand, further assessment of all women with symptoms possibly leads 
to additional false-positive cases (study II), lower efficacy of the programme, and 
anxiety or other psychological distress among the women. In addition, variation in 
the cancer detection rates or false-positive findings by symptom status implies that 
not all symptoms are equally sensitive and may in turn lower the positive predictive 
value of recall. As about 97% of the screening visits were asymptomatic, the number 
of additional further assessment services would be rather small, as well as would yield 
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a small improvement in the programme’s overall performance and outcome. Still, 
high quality and clinically appropriate services are important for women presenting 
with symptoms at screening mammography. The potential of new imaging 
techniques such as digital breast tomosynthesis to improve diagnostic accuracy of 
imaging in the cases of symptoms (primarily a lump) could help to decrease false 
positive recalls if no abnormality is seen on 3-dimensional mammography. Especially 
in cases of mammograpically dense breast, tomosynthesis has been found to increase 
cancer detection rate by revealing a tumor that is hidden in the dense tissue (Conant 
et al., 2019; Skaane et al., 2019). So far, tomosynthesis is used in Finland as part of 
further assessment but not as part of primary screening technique. A health 
economic assessment of providing such a comprehensive services to all women 
presenting with symptoms should be made.  
The higher incidence of interval cancers in symptomatic women within 6 months 
after a negative mammography is a huge concern for radiologists. This indicates that 
further assessment would be needed if symptoms are present even though this will 
result in loss of specificity. In addition, because of the high incidence of advanced 
interval breast cancers before the next screening invitation and higher risk of cancer 
diagnosis in the subsequent screening round in the symptomatic women, a potential 
improvement in further assessment would not be clearly sufficient. Furthermore, the 
programme lacks surveillance or follow-up of symptomatic women who did not 
undergo further assessment, as these women are more prone to seek out private 
mammography. The results from study IV showed a substantial difference in the 
mortality rates within five years after visits with and without symptoms. Women 
need to be better informed  and made aware that if a symptom occurs, it is 
inadvisable to wait until the next invitation to the programme. Improved guidelines 
on further assessment and a reduction in the screening interval for women 
presenting with symptoms as suggested by our study might help to reduce the 
screening inequities and improve the performance of the mammography screening 
programme.   
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6.5 Summary and conclusions 
The importance of breast symptoms reported by women during the screening visit 
was evaluated within the population-based mammography screening programme for 
breast cancer. The study used the whole cohort of women with or without breast 
symptoms since the early years of the screening programme (from 1992) until the 
most recent year available (2014). Thus, the results are directly applicable to routine 
use. Finland’s three health care registries were used to obtain information on 
symptoms and associated cancer outcomes, including time and cause of death.   
     Our study showed a strong positive association between breast symptoms and 
the risk of screen-detected cancers, interval cancers and breast cancer mortality as 
compared to screening visits without symptoms. The programme performance 
indicators such as sensitivity and positive predictive value (PPV) were higher in those 
who reported symptoms as compared to those without symptoms at screening visit. 
However, we also found a higher risk of false-positive test results in the symptomatic 
women. 
     Of the three most common breast symptoms, a lump was a strong predictor 
of breast cancer and of breast cancer mortality and all-cause mortality. Screening 
visits with a retraction or nipple discharge were also increasingly associated with the 
outcomes. 
     We found that in screening visits with two symptoms, a lump and retraction, 
the cancer risk was multiplicative. However, we did not find an age-related increase 
in the cancer risk, except for the symptom of nipple discharge. Given the limited 
sensitivity and specificity of breast symptoms, prevention programmes based on 
clinical examination only would not provide a sufficient benefit for breast cancer 
control. This reinforces the importance of a mammography screening programme 
in resourceful settings like Finland.       
     One important harm is the large numbers of false-positive test findings in 
symptomatic women as compared to asymptomatic women. This creates challenges 
for radiologists to correctly identify abnormalities in the mammogram that are likely 
to develop to a malignant tumour and decide whether or not to recall the woman. 
This should be carefully considered to maintain a balance of benefits and harms of 
screening for individual women. 
     Our study showed that the risk of screen-detected and interval breast cancers 
was higher in those who reported any of the three symptoms. This indicates that all 
three symptoms are clinically important in detecting cancers. A better diagnostic 
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workup is needed in the symptomatic women, including detailed indication for 
biopsies in the further assessment phase. 
     One of the key findings is that interval breast cancer incidence increased rather 
rapidly after the negative screening episode in women with symptoms. This is a clear 
concern for the programme and indicates that these women should have further 
contact with health care centres due to concern or anxiety. Also, the high incidence 
of advanced interval breast cancers shortly after a negative episode indicates the need 
for a follow-up visit shortly after the negative examination, especially in women with 
a lump or nipple discharge. 
     The cumulative breast cancer mortality and all-cause mortality pattern 
remained higher in the symptomatic group throughout the long follow-up time 
available in our study. The substantial high mortality rates within a period of five 
years after the screening visit with symptoms reinforces the need for a detailed 
further assessment and biopsy recommendation. Continuous efforts to increase 
awareness in women about breast symptoms and encouraging them to seek care even 
prior to invitations are very important. Improvement in the guidelines on screening 
and clinical services could reduce inequalities among these women. However, we 
could not assess the socio-economic differences in the mortality between the 
symptomatic and asymptomatic groups. Understanding the detailed background 
information as well as studying or analysing the detailed screening procedure in 
symptomatic women will help answer most of the questions that this study was not 
able to.     
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6.6 Future perspectives 
As is often the case, while trying to answer one question we ended up asking more. 
One important issue to address in the future is how to optimally use information on 
breast symptoms in the breast cancer-screening programme: 
x From the programme perspective, information on breast symptoms needs 
to be collected more uniformly and symptoms should be asked about during 
mammography screening visits. An important challenge is the tender 
process; hence, collecting detailed information on symptoms is an additional 
administrative burden.  
x Future studies should also focus on other important risk factors such as 
breast density, use of hormones, and family history of breast cancer, all of 
which might provide insight into the association between symptoms and 
cancer risk. In addition, studying the difference in socio-economic status 
between symptomatic and asymptomatic women might help us to 
understand the association more broadly.  
x Also, it would be useful to study the histological classification of tumours, 
tumour size, grade and lymph node involvement in symptomatic women 
who were diagnosed with breast cancers and then compare them to 
asymptomatic women with otherwise similar characteristics.  
x More women with breast symptoms should be recalled for further 
assessment, including appropriate core biopsy. One option would be to have 
a shorter screening interval, especially for women who report a lump but are 
not referred for surgery. The impact of such strategies, if implemented, 
should be closely monitored and assessed.  
x National screening guidelines on women presenting with breast symptoms 
need to be more specific and clearer. The evidence from our study could be 
used to improve EU guidelines or any international guidelines on screening 
and further assessment, specifically for those women who present with 
breast symptoms at screening visits.  
x Recent studies have shown that immigrant women have lower 
mammography screening attendance than native women but similar 
incidence of breast cancer. Those women might also have higher prevalence 
of symptoms, thus leading to higher risk of breast cancer. Future studies 
need to be conducted among those target groups as well. 
Much is to be done in the field of breast cancer epidemiology, specifically 
concerning women with breast symptoms. In general, this extends beyond Finland 
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to other high-incidence countries that have mammography screening programmes. 
Our study is an initial example that shows the importance of collecting and analysing 
information on breast symptoms by the Finnish programme, as well as the 
importance of not excluding women from invitation to screening. The study findings 
have clearly shown that other countries could benefit from collecting information 
on symptoms and from following women thereafter. Our findings are useful to 
countries that have recently started screening programmes, especially upper middle 
income countries. Of equal importance is the inclusion of all women in the target 
age groups in screening and to not exclude those with symptoms. 
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The study purpose was to assess association of symptoms at screening visits with detection of breast cancer among women
aged 50–69 years during the period 2006–2010. Altogether 1.2 million screening visits were made and symptoms (lump,
retraction, secretion etc.) were reported either by women or radiographer. Breast cancer risk was calculated for each symptom
separately using logistic regression [odds ratio (OR)] and 95% confidence intervals (CIs). Of the 1,198,410 screening visits
symptoms were reported in 298,220 (25%) visits. Breast cancer detection rate for women with and without symptoms was 7.8
per 1,000 and 4.7 per 1,000 screening visits, respectively, whereas lump detected 32 cancers per 1,000 screens. Women with
lump or retraction had an increased risk of breast cancer, OR56.47, 95% CI 5.8927.09 and OR52.19, 95% CI 1.92–2.49,
respectively. The sensitivity of symptoms in detecting breast carcinoma was 35.5% overall. Individual symptoms sensitivity
and specificity ranged from, 0.66 to 14.8% and 87.4 to 99.7%, respectively. Of 5,541 invasive breast cancers, 1,993 (36%)
reported symptoms at screen. Breast cancer risk among women with lump or retraction was higher in large size tumors
(OR59.20, 95% CI 8.08–10.5) with poorly differentiated grades (OR55.91, 95% CI 5.03–6.94) and regional lymph nodes
involvement (OR56.47, 95% CI 5.67–7.38). This study was done in a setting where breast tumors size is generally small,
and symptoms sensitivity and specificity in diagnosing breast tumors were limited. Importance of breast cancer symptoms in
the cancer prevention and control strategy needs to be evaluated also in other settings.
Early detection of breast cancer through organized screening in
average risk women has reduced mortality from the disease.1,2
In Finland, the national organized mammography screening
program has been reported to reduce the incidence-based mor-
tality from breast cancer by approximately 20–28% among
those invited.3 Many, even though not all, breast cancer screen-
ing programs include an examination of breasts done by the
radiographer and/or reporting of symptoms by the woman at
the screening visit.1,4 Symptoms ﬁndings from such examina-
tion could convey to diagnostic work-up in the screening cen-
ters, as well as indicate a differential risk of breast cancer.
Over-diagnosis and unnecessary treatment of apparently
healthy women in mammography screening raise the ques-
tion about beneﬁts versus harms of screening over clinical
breast examination.5 Many countries where mammography
screening is not organized at population level but with the
increasing awareness about breast cancer, patients may pres-
ent with breast complaints.6 Hence in such situation, detec-
tion of breast cancer cases mostly rely on breast complaints.
Research on the possible symptoms can provide feedback for
the clinicians and help in making decisions when reading
screening ﬁlms and in further investigations (recall or refer-
ral).4 Few studies have highlighted the relevance of assessing
symptoms at screening diagnostic mammography.4,7–9
So far, no studies till date have studied the association
of symptom and breast cancer risk at population level.
There is a possibility to learn about beneﬁts of assessing
symptoms during screening as well as to improve the pro-
cedures by reducing unnecessary diagnostics and false posi-
tive ﬁndings. Moreover, for developing countries, where
high technology for detecting early cancer is not feasible,
symptoms can be used as an indication for early diagnos-
tics. Provided that adequate resources are available for con-
ﬁrmation and treatment, this could prevent late stage
presentation of cancer.7
The aim of the study was to assess the association of
symptoms with the occurrence of breast cancer and to
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analyse the cross-sectional clinical validity of symptoms
among screened women under the organized breast cancer-
screening program.
Materials and Methods
This study is based on breast cancer screening data provided
by the Mass Screening Registry (MSR) of the Finnish Cancer
Registry (http://www.cancer.ﬁ/syoparekisteri/en/). The MSR
receives information on the breast cancer screening program
through the population ﬁles and the screening centers.10
Registration is based on the law of personal data in the
health-care and the Government Decree on Screenings,
1,339/2,011, and the respective recommendations published
by the National Research and Development Centre for Wel-
fare and Health.11
The Finnish breast cancer-screening program targets women
aged 50–69 years every 2 years. A personal invitation letter is
sent by mail with a preﬁxed time and place of screening. All
women in the target age are invited with no exclusions. At the
screening clinic woman may present with symptoms or no
symptoms. Women are asked (or to ﬁll in the form) whether
they had any symptoms during the past 2 months. The nurse
then examines the breast. Symptoms are recorded in the mam-
mography screening form. After then, breasts are examined by
mammography. After interpretation of the results those with
mammography positives are recalled for further examination.
Women who are mammography negative are sent home and
invited after 2 years for the next biennial screening round. Phy-
sician examines the breast of the recalled women. Women may
be healthy or referred for diagnostic workup at hospital. Those
with cancers are followed up until death (mortality).10
For the current study, information on women aged 50–69
years who had breast cancer screening during the years
2006–2010 were retrieved. The ﬁrst round of screening starts
at the age of 50–51 years. The study is based on tabular
information and originates from data recorded on the mam-
mography screening form (http://www.cancer.ﬁ/syoparekis-
teri/joukkotarkastusrekisteri/) for every woman who was
screened during that period of time. Altogether 1,454,143
invitations were made during the period, of which 1,241,486
screening visits were made (attendance 85.4%). In all, 38,647
visits (3.11%) were excluded because of incomplete informa-
tion on either the clinical examination or on self-reported
symptoms. Furthermore, 4,429 (0.36%) visits were excluded
because of not complying with the age range. The ﬁnal data
set contains 1,198,410 screening visits from all over Finland.
Symptoms that were reported include lump, retraction, scar,
secretion and mole. Outcome variables were histologically
conﬁrmed breast cancers (both invasive and in situ) and
benign ﬁndings. Some tumor characteristics (tumors size and
grade) were also available.
In the current analysis, women who had a given symptom
at screen in either or both breasts were considered as symp-
tomatic. Information on breast symptoms was dichotomized
for any as well as for each individual symptom separately.
The outcome was categorized as malignant (in-situ and inva-
sive breast cancers) and benign ﬁnding (other histology). The
age of screened women was categorized into four groups as
“50–54,” “55–59,” “60–64” and “65–69.” To do the homoge-
neity test of symptoms with age, age-groups were made as
continuous variables where age-group 50–54 years indicate
“0,” 55–59 years indicate “1,” 60–64 years indicate “2” and
65–69 years indicate “3.” In classifying histologically con-
ﬁrmed tumors two categories of tumor size were made: “less
than 20 mm” and “20–150 mm.” Tumor grades were classi-
ﬁed as “well-differentiated,” “moderately differentiated” and
“poorly differentiated.” Tumor spreading was classiﬁed
according to the TNM classiﬁcation of tumors published by
International Union Against Cancer (UICC) in 2002.12
Statistical analysis
Breast cancer detection rate (number of cancer cases detected
divided by number of screening visits) was calculated for indi-
vidual symptoms as well as for all possible pairwise combina-
tion of symptoms. Logistic regression model was used to
calculate the crude and adjusted odds ratios (ORs) with 95%
conﬁdence interval (CI) using Wald statistics for individual
terms. The univariate logistic regression model was used to esti-
mate the age-adjusted association of symptom with the occur-
rence of breast cancer. For calculating the joint exposure effects
and homogeneity analysis likelihood ratio statistics was used.
Effects by individual and combined symptoms (self-reported
and radiographer reported) as well as pairwise analysis of symp-
toms with all possible combinations were also estimated. All the
statistical analyses were two-sided, and a p value 0.05 was
considered to be statistically signiﬁcant. The statistical analyses
were carried out using STATA software release 11.0.
What’s new?
A key component of breast cancer screening programs is the collection of data on symptoms at the time of screening visit. In
many cases, however, the data are not subsequently analyzed for relationships between symptoms and breast cancer diagno-
sis. Based on analysis of data from 1.2 million screening visits recorded in the Finnish Cancer Registry, the present report
describes a significant association between breast cancer risk and symptoms either self-reported by patients or detected by
radiographers. Risk was highest for breast lumps reported at screening. Importantly, the findings also highlight limitations
regarding the clinical significance of symptoms.
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To analyze the cross-sectional validity of the symptoms,
sensitivity and speciﬁcity were estimated. True positives are
here those with a “positive” symptom and with breast cancer
and vice-versa for true negatives. Breast cancer included inva-
sive and in situ carcinoma of the breast, and analyses were
done also separately for these two diagnosis categories when
relevant. False positives are here those with a positive symp-
tom but no breast cancer whereas false negatives are those
with no symptom but had breast cancer. Sensitivity was here
deﬁned as the number of visits with screen-detected malig-
nant cancers in those who had symptoms (true positives for
symptoms) divided by the total number of visits with breast
cancer. Speciﬁcity was the number of visits with no symptoms
and no malignant ﬁnding (true negatives for symptoms),
divided by the total number of visits with no malignant ﬁnd-
ings. CIs for sensitivity and speciﬁcity were produced with the
Wilson score method.13 The positive predictive value (PPV) is
the likelihood of cancer detected among those who had symp-
toms. CI for PPV was calculated using the method described
by Simel et al.14 We considered lump or retraction as clini-
cally relevant symptoms while reporting and analyzing symp-
toms information on histological conﬁrmed tumors.
Results
A total of 1,198,410 screening visits were made in 2006–2010
and out of these, a histologically conﬁrmed breast cancer
(including in-situ cases) was diagnosed in 6,009 (0.5%)
women at screen. In this period, the national decree of
screening was given and women aged 60–69 years were also
included into the target population if they were born in 1947
or later. Thus, the number of screened women increased year
by year clearly between 2006 and 2010, i.e., 192,892 and
264,678, respectively. Altogether 298,220 visits with at least
one symptom out of 1,198,410 visits (24.9%) were reported in
this period (Table 1). Lump was reported in 15,587 (1.30%)
screening visits and retraction was reported in 20,880 (1.74%)
visits. The percentage of women who reported symptoms (out
of total screened) increased clearly by age of the women,
21.8% in age-group 50–54 years and 30% in age group 65–69
years, respectively. Screen positive women (who were recalled)
were 30,392 (2.5%) out of which 9,659 (32%) reported any of
the symptoms. The percentage of women out of total screen-
ing visits that were referred for further assessment was 0.75%.
Breast cancer detection rate of lump was 31.9 per 1,000
screening visits whereas detection rate of retraction and
secretion was 11.6 per 1,000 and 10.8 per 1,000 screening vis-
its, respectively. The age-adjusted risk of breast cancer in
women who reported a lump was 6.61 (95% CI 6.03–7.26)
times higher compared to those with no symptoms (Table 2).
Similarly, the risk in women who reported retraction or secre-
tion was more than twofold, OR5 2.11, 95% CI 1.86–2.41
and OR5 2.14, 95% CI 1.58–2.89, respectively, compared to
women who reported no symptoms. Reporting a scar or mole
indicated a small increase in the risk of breast cancer com-
pared to those with no symptoms, i.e., OR5 1.26, 95% CI
1.17–1.35 and OR5 1.16, 95% CI 1.09–1.25, respectively.
The risk of breast cancer in women who reported lump
was higher in all age groups compared to women with other
symptoms. Women who reported lump and/or retraction had
a signiﬁcant increase in breast cancer risk across age groups.
Women who reported secretion had an increase in trend of
breast cancer risk with age (Fig. 1). The joint effect of symp-
toms with two possible combinations was measured simulta-
neously. The cancer detection rate of lump and retraction
combined was 102 per 1,000 screening visit whereas com-
bined lump and secretion was 26 per 1,000 screening visits.
Similarly, the combined cancer detection rate of retraction
and scar was 12 per 1,000 screening visits. The combined
effect of lump and retraction showed a 23-fold (OR5 22.6,
95% CI 16.5–30.8) increase in the risk of breast cancer com-
pared to women with no lump or retraction. Similarly, the
joint effect of lump and scar showed a sixfold (OR5 5.37,
95% CI 4.31–6.69) increase in the risk of breast cancer com-
pared to women with no lump or scar (Table 3).
Overall, 2,314 women who had any of the symptoms were
diagnosed with breast cancer at screen. The sensitivity to
detect cancer for women with any of the symptoms was 35.5%
(95% CI 34.3–36.6%) whereas speciﬁcity was 75.2% (95% CI
75.1–75.3%; Table 4). The sensitivity to detect cancer was 8%
in women who had a lump whereas in case of retraction the
sensitivity was 4%. However, the speciﬁcity was high for lump
and retraction, 98.7 and 98.3%, respectively. Scar and mole
both had a sensitivity of 15% each whereas speciﬁcity was low
for these symptoms, 88.3 and 87.4%, respectively.
Altogether 5,541 invasive breast cancers were detected at
screen out of which 1,993 (36%) were reported with symptoms
at the time of screening and 652 (32.7%) reported lump or
retraction only. In all, 70% of the invasive cancers were less
than 20 mm in diameter. The presence of lump or retraction
increased from 8% in tumors less than 20 mm of size to 22% in
tumors of 20–150 mm in size (Table 5). The probability of hav-
ing age-adjusted invasive breast cancer was signiﬁcantly higher
(OR5 4.31, 95% CI 3.96–4.69) in those who reported lump or
retraction compared to those with no lump or retraction.
Women with lump or retraction had a signiﬁcantly higher age-
adjusted risk for big tumors than nonsymptomatic women,
OR5 2.84 (95% CI 2.53–3.19) in tumors less than 20 mm and
OR5 9.20 (95% CI 8.08–10.5) in 20–150 mm size tumors. The
probability of having poorly differentiated tumors was signiﬁ-
cantly higher (OR5 5.91, 95% CI 5.03–6.94) in women who
reported symptoms than in those without symptoms. The prob-
ability of having tumors in regional lymph nodes was signiﬁ-
cantly greater in women with symptoms compared to those
with no symptoms, OR5 6.47, 95% CI 5.67–7.38.
Discussion
The purpose of the study was to examine the association
between symptoms at the screening visit and detection of
breast cancer at screen. In addition, we described the size
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and grade of tumor in relation to symptoms at screen in
women who attended screening and were diagnosed with a
breast tumor. The large dataset of about 1.2 million screening
visits allows studying breast cancer risk at the population
level among women who reported symptoms at screening.
The study found a signiﬁcant association between all reported
Table 1. Symptoms2 reported during the screening visits at different time-periods and by age, recall, or referral due to screening results
Total screening
visits Lump (%) Retraction (%) Scar (%) Mole (%) Secretion (%)
Any of the
symptoms (%)1
Year
2006 192,892 2,570 (1.3) 3,425 (1.8) 22,239 (11.5) 27,411 (14.2) 726 (0.4) 50,402 (26.1)
2007 235,304 3,044 (1.3) 3,858 (1.6) 27,819 (11.8) 31,239 (13.3) 879 (0.4) 60,106 (25.5)
2008 237,389 3,011 (1.3) 4,297 (1.8) 27,821 (11.7) 30,937 (13.0) 797 (0.3) 60,117 (25.3)
2009 268,147 3,346 (1.2) 4,542 (1.7) 31,492 (11.7) 30,327 (11.3) 722 (0.3) 63,462 (23.7)
2010 264,678 3,616 (1.5) 4,758 (1.8) 30,766 (11.6) 31,115 (11.8) 841 (0.3) 64,133 (24.2)
Age
50–54 469,594 6,932 (1.5) 6,794 (1.4) 44,587 (9.5) 52,734 (11.2) 2,081 (0.4) 102,538 (21.8)
55–59 339,635 4,095 (1.2) 6,368 (1.9) 41,029 (12.1) 42,885 (12.6) 943 (0.3) 85,715 (25.2)
60–64 306,227 3,622 (1.2) 6,012 (1.9) 42,552 (13.9) 42,343 (13.8) 721 (0.2) 85,177 (28.8)
65–69 82,954 938 (1.1) 1,706 (2.1) 11,969 (14.4) 13,067 (15.7) 220 (0.3) 24,790 (29.8)
Recall
Yes 30,392 2,205 (7.2) 724 (2.4) 4,210 (13.8) 3,976 (13.1) 310 (1.0) 9,659 (31.7)
No 1,168,018 13,382 (1.1) 20,156 (1.7) 135,927 (11.6) 147,053 (12.6) 3,655 (0.3) 288,561 (24.7)
Referral
Yes 8,093 613 (7.6) 278 (3.4) 1,248 (15.4) 1,169 (14.4) 87 (1.1) 2,876 (35.5)
No 1,073,462 13,979 (1.3) 19,429 (1.8) 129,050 (12.0) 141,470 (13.2) 3,559 (0.3) 276,507 (25.7)
Total 1,198,410 15,587 (1.3) 20,880 (1.7) 140,137 (11.7) 151,029 (12.6) 3,965 (0.3) 298,220 (24.9)
1Percentage (%) in the bracket means any of the symptoms out of total screening visits.
2Symptoms include women, radiographer reported or both.
Table 2. Age-adjusted odds ratios (OR) of breast cancer (including in situ and benign tumors) with 95% conﬁdence intervals (CI) among
women with symptoms1 compared to women with no symptoms
Cases (%) Total (%)
Detection rate
(per 1,000)
OR (95% CI)*
adjusted with age
Lump
Yes 497 (3.19) 15,587 (1.30) 31.9 6.61 (6.03–7.26)
No 6,027 (0.51) 1,189,601 (98.7) 5.07 Ref.
Retraction
Yes 242 (1.16) 20,880 (1.74) 11.6 2.11 (1.86–2.41)
No 6,282 (0.53) 1,177,530 (98.3) 5.33 Ref.
Scar
Yes 966 (0.69) 1,40,137 (11.7) 6.89 1.26 (1.17–1.35)
No 5,558 (0.53) 1,058,273 (88.3) 5.25 Ref.
Secretion
Yes 43 (1.08) 3,965 (0.33) 10.8 2.14 (1.58–2.89)
No 6,481 (0.54) 1,194,364 (99.7) 5.43 Ref.
Mole
Yes 963 (0.64) 1,51,029 (12.6) 6.38 1.16 (1.09–1.25)
No 5,561 (0.53) 1,047,299 (87.4) 5.31 Ref.
Total 6,524 (0.54) 1,198,410 (100.0)
1Symptoms include women, radiographer reported or both.
Abbreviations: OR: odds ratio; CI: conﬁdence interval; ref.: reference.
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symptoms and the occurrence of breast cancer. A breast
lump at screen indicated the highest breast cancer risk.
In this study symptoms were either self-reported or radiog-
raphers reported and the rate of breast cancer associated with
symptoms were calculated. Symptoms were reported in 25% of
the screening exams. This is higher than previously reported
in a study on postmenopausal women where the prevalence of
symptoms was below 10%.7 The explanation may be that in
our study more symptoms were included and symptoms were
considered valid whether reported by women or by the radiog-
rapher. In studies reporting symptoms at diagnostic mammog-
raphy exams the prevalence has been more than 30%.7,8,15 The
reason for high prevalence of symptoms in diagnostic mam-
mographic exams may be due to selection of women at
increased risk of breast cancer7,8,15 and premenopausal women
in whom prevalence of symptom is higher.6
The overall proportion of women with breast cancer among
those reporting symptoms was 0.78% in our study. The recall rate
(mammography positives) among women with symptoms was
3.24%, whereas only 1.73% of women with no symptoms were
recalled. Similarly, the proportion of women who referred for fur-
ther assessment was greater in those with symptoms compared to
women with no symptoms, i.e., 0.96 versus 0.44%, respectively.
Aiello et al.7 reported that 6.6% of women with symptoms at
diagnostic examination and 1.3% of women at screening exami-
nation were diagnosed with breast cancer. Williams et al.4 study
on women who had mammography screening found the breast
cancer rate of 0.5% in women with symptoms which is lower
than in our study (0.8%). However, they evaluated only those
women with “signiﬁcant” breast symptoms as deﬁned by Breast
Test Wales (BSW) guidelines.16 The Seltzer9 study reported
higher proportion (16%) of breast cancer diagnosed among
women with symptoms or prior abnormal mammography that
were referred for diagnostic examination. This study found the
cancer rate of 7.6, 3.7 and 14.9% in patient with breast lump,
retraction and scar, respectively, which is little lower than the
study by Lumachi et al.17 That study found a cancer rate of 3.2,
16.4 and 12.0%, respectively, in patient with breast pain, lump
and nipple discharge.17 In another study by Sterns,18 breast cancer
rate was 37, 11 and 3% in patients with breast mass, nipple dis-
charge and lump, respectively. One reason for the differences may
Table 3. Odds ratios (ORs) of breast cancer with 95% conﬁdence intervals (CI) for joint exposure to symptoms1
Symptoms Screened women Cancer cases (%)
Detection rate
(per 1,000) OR 95% CI
Lump#retraction 36,036 695 (1.93) 19.3
0 0 1,162,374 5,829 (0.50) 5.01 Ref. Ref.
0 1 20,449 198 (0.97) 9.68 1.94 1.68–2.24
1 0 15,156 453 (2.99) 28.9 6.15 5.55–6.74
1 1 431 44 (10.2) 102 22.6 16.5–30.8
Lump#scar 152,515 1,380 (0.90) 9.05
0 0 1,045,895 5,144 (0.49) 4.92 Ref. Ref.
0 1 136,928 883 (0.64) 6.45 1.31 1.22–1.41
1 0 12,378 414 (3.34) 33.4 7.0 6.32–7.75
1 1 3,209 83 (2.59) 25.9 5.37 4.31–6.69
Retraction#scar 157,121 1,162 (0.74) 7.4
0 0 1,041,289 5,362 (0.51) 5.15 Ref. Ref.
0 1 136,241 920 (0.68) 6.75 1.31 1.22–1.41
1 0 16,984 196 (1.15) 11.5 2.26 1.95–2.60
1 1 3,896 46 (1.18) 11.8 2.31 1.72–3.09
1Symptoms include women, radiographer reported or both.
Abbreviations: 0: absence of symptom; 1: presence of symptom; OR: odds ratio; CI: conﬁdence interval; ref.: reference.
Figure 1. Breast cancer risk among women having symptoms
reported by age groups.
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be that our study was done among the general population and
most women come for screening on a regular basis (once in every
2 years). Moreover, in our study women reported only symptoms
that occurred in the past 2 months and radiographer reported
those symptoms detected at the time of screening visit. The rea-
son for higher rates in other studies17,18 was that both studies
were done among symptomatic women who had higher risk of
developing cancer. However, due to variation in early detection
program and collected symptoms information as well as varying
age of the women at either screen or diagnostic examination than
our study, results are not directly comparable with the current
study.
In this study, the risk of breast cancer was found to be
signiﬁcantly associated with the occurrence of symptoms.
The risk of developing breast cancer was sevenfold in women
having a lump and the risk was almost similar across the age
group. Aiello et al.7 reported a risk of more than threefold in
women who had a lump in the screening exam or diagnostic
exam but no signiﬁcant association between nipple discharge,
breast pain and breast cancer risk. Moreover, our study
showed a threefold increase in risk in women who had
retraction in their breast and a small increase in risk in those
who reported scar and mole. We are unaware of other epide-
miological studies that would have examined the association
between retraction, scar and the breast cancer risk. Two-way
joint effects of symptoms showed a signiﬁcant 23-fold breast
cancer risk in women who reported lump and retraction and
a 6-fold risk in women who reported lump and scar. The
higher risk of breast cancer in our study may be due to the
information about breast symptoms systematically collected.
A study by Sarkeala et al.3 in Finland found a 1.56 (95%
CI5 1.25–1.91) times higher death rate in women who had
no screening visits. The interval cancers, since screening visits
are made once in every 2 years, can be more aggressive than
screen-detected cancers. Hence, the risk might be even higher
in women who had symptoms and are not screened.
In our study breast cancer rate among women with any of
the given symptoms was 0.66% in age-group 50–59 years and
0.99% in age-group 60–69 years. Sterns’18 study in sympto-
matic patients found the cancer rate to be signiﬁcantly age-
related, being 0.8% in women younger than 40 years and 5% in
those between 41 and 55 years. Kerin et al.19 evaluated the 585
symptomatic patients found breast cancer rate of 2.2% in
patient aged 40–49 years, 4.5% in patient aged 50–59 years and
3.1% in patient aged more than 60 years of age. In our study
women who reported a lump or retraction showed signiﬁcantly
higher risk of breast cancer in all age-groups compared to non-
symptomatic women. Women with other symptoms had a
nonsigniﬁcantly higher breast cancer risk across age groups.
The p value test for homogeneity showed no age related breast
cancer risk with an exception of secretion (p value <0.05).
The sensitivity of reporting any symptom in detection of
invasive carcinoma was 35.5% in the present study, which is
lower than that reported by others.20–22 However, Harvey et al.20
and Kerlikwoske et al.21 measured sensitivity based on the mam-
mography ﬁndings and Bobo et al.22 based the sensitivity calcu-
lation on clinical breast examination. A community based study
among asymptomatic women in United States reported lower
sensitivity than found in our study, between 18.1 and 21.6%
based on clinical breast examination.23 Findings from a random-
ized controlled trial of breast cancer screening by clinical breast
examination in India showed a moderate sensitivity and high
speciﬁcity, 51.7 and 94.3%, respectively, but PPV was lower than
found in our study.24 In our study, the sensitivity of lump,
retraction, scar and mole was 7.7, 3.7, 14.8 and 14.8%, respec-
tively, while high speciﬁcity of 99% was reported by lump and
retraction. We are not aware of any other studies that measured
the clinical validity of symptoms at screen and hence our study
ﬁndings are not directly comparable to other studies. The low
sensitivity of any speciﬁc symptom in our study may be
explained by the magnitude of diagnostic activities, several
rounds of screening in the program, and access to mammog-
raphy services outside the screening program. Thus, both the
population and the tumors found by screening are different
from those in the trial from India.24
Another purpose of our study was to assess tumor character-
istics (size and grade) in relation with breast cancer symptoms.
We found that close to 70% of invasive breast cancers detected
by screening were less than 20 mm of size. Sankaranarayanan
et al.24 study reported a signiﬁcantly lower percentage of tumors
Table 4. Clinical validity of symptoms1 in terms of sensitivity, speciﬁcity and positive predictive value (PPV)
Clinical validity Lump Retraction Scar Secretion Mole
Any of the
symptoms
True positives 497 242 966 43 963 2,314
True negatives 1,176,796 1,171,248 1,052,715 1,187,883 1,041,738 895,980
False positives 15,090 20,638 139,171 3,922 150,066 295,906
False negatives 6,027 6,282 5,558 6,481 5,561 4,210
Sensitivity % 7.62 (7.04–8.32) 3.71 (3.27–4.20) 14.8 (14.0–15.7) 0.66 (0.48–0.89) 14.8 (13.9–15.7) 35.5 (34.3–36.6)
Speciﬁcity % 98.7 (98.7–98.8) 98.3 (98.2–98.3) 88.3 (88.3–88.4) 99.7 (99.7–99.7) 87.4 (87.3–87.5) 75.2 (75.1–75.3)
Positive predictive
value %
3.19 (2.92–3.48) 1.16 (1.02–1.32) 0.69 (0.65–0.73) 1.08 (0.79–1.47) 0.64 (0.60–0.68) 0.78 (0.74–0.81)
1Symptoms include women, radiographer reported or both.
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less than 20 mm in size compared to our study, 18.8% versus
69.3%, respectively. The high proportion of invasive cancers of
small size highlights the importance of organized screening pro-
gram where tumors can be detected at early stage of disease.
Similarly, other studies have found quite signiﬁcant difference in
tumors characteristics between screen detected and clinical
breast cancer cases.25–29 A study by Miller et al.5 among women
with annual screening in age 40–59 found that 68% of the palpa-
ble cancers had a mean tumor size of 21 mm, which is signiﬁ-
cantly higher than in our study. The probability of detecting
invasive tumors with poor differentiation (high grade) was sig-
niﬁcantly higher in those who reported symptom at screen com-
pared to those with no symptom.
To the best of our knowledge, our study is the largest
study done on breast cancer symptoms, either self-reported
or radiographer reported, and breast cancer risk at screen.
Our ﬁndings reinforce the importance of evaluating symp-
toms as a predictor of breast cancer and warrant extra con-
sideration while evaluating mammograms of women with
symptoms. Also, continual maintaining of the information
about symptoms at screening visits is useful for the clinician
as well as for epidemiological research.
This study was limited to those women who attended
screening and the size of breast tumors was generally small.
Thus, the sensitivity and speciﬁcity of diagnosing breast
tumors based on symptoms were limited. Also, breast cancer
cases detected outside screening were not included. It may be
that women with symptoms also had other risk factors (like
dense breasts or positive family history) which might con-
found the observed effect. A potential limitation of this cross-
sectional study is the lack of descriptive information other
than age so no adjustment for confounders such as breast den-
sity, family history of breast cancer or number of previous
screens was possible in the multivariate analysis. The study
was cross-sectional and no follow-up or subsequent round of
screening was included. There was a possibility that knowing
the symptom status may have already inﬂuenced the radiology
result. Given the low sensitivity of symptoms in our study it is
likely that a prevention program based on clinical examination
would not provide sufﬁcient beneﬁt for breast cancer control
in Finland and the mammography screening program is still
justiﬁed. The study provides limited evidence that reporting
symptoms at screen was associated with aggressive tumors,
i.e., tumors with poor prognosis. This study cannot say about
the impact in low resource setting with currently no breast
cancer screening services. However, considering the higher
risk of breast cancer in women with symptoms, clinical breast
examination together with the availability of diagnostic serv-
ices could help in detecting large size tumors. Importance of
breast cancer symptoms in the cancer prevention and control
strategy needs to be evaluated also in other settings.
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Abstract Mammography has been found effective as the
primary screening test for breast cancer. We estimated the
cumulative probability of false positive screening test
results with respect to symptom history reported at screen. A
historical prospective cohort study was done using indi-
vidual screening data from 413,611 women aged
50–69 years with 2,627,256 invitations for mammography
screening between 1992 and 2012 in Finland. Symptoms
(lump, retraction, and secretion) were reported at 56,805
visits, and 48,873 visits resulted in a false positive mam-
mography result. Generalized linear models were used to
estimate the probability of at least one false positive test and
true positive at screening visits. The estimates were com-
pared among women with and without symptoms history.
The estimated cumulative probabilities were 18 and 6 % for
false positive and true positive results, respectively. In
women with a history of a lump, the cumulative probabili-
ties of false positive test and true positive were 45 and 16 %,
respectively, compared to 17 and 5 % with no reported
lump. In women with a history of any given symptom, the
cumulative probabilities of false positive test and true pos-
itive were 38 and 13 %, respectively. Likewise, womenwith
a history of a ‘lump and retraction’ had the cumulative false
positive probability of 56 %. The study showed higher
cumulative risk of false positive tests and more cancers
detected in women who reported symptoms compared to
women who did not report symptoms at screen. The risk
varies substantially, depending on symptom types and
characteristics. Information on breast symptoms inﬂuences
the balance of absolute beneﬁts and harms of screening.
Keywords Breast cancer symptoms  False positive  True
positive  Mammography  Screening  Lump
Abbreviations
IARC International Agency for Research on Cancer
FCR Finnish Cancer Registry
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Introduction
Organized screening programs for breast cancer have been
estimated to reduce breast cancer mortality by about 23 %
among those invited. On the other hand, however, it has
also been shown to increase the risk of cumulative false
positive results by about 20 % [1]. These estimates
describe mainly screening programs that invite women
aged 50–69 or 50–74 years. There is no clear evidence on
effectiveness of systematic clinical breast examination
without mammography or of breast self-examination [1, 2].
In addition to sole mammography as the screening test,
some programs or trials have performed clinical or physical
examination [3]. Clinical examination means systematic
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article (doi:10.1007/s10549-016-3931-8) contains supplementary
material, which is available to authorized users.
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palpation by speciﬁcally trained staff [3]. However, the
clinical examination in Finland is done by collecting self-
reported information on symptoms during the screening
examination as well as inspection of breasts by the
radiographer.
Self-reported symptoms as well as radiographer
reports on observations have been a part of the mam-
mography screening program in Finland, since the pro-
gram started in the late 1980s [3, 4]. Cross-sectional
studies have indicated that symptoms have important
consequences on the performance of screening [5–7].
There is a risk that harms of screening may increase, as
information on symptoms launch further assessments not
dealing with breast cancer. The ﬁndings of the physical
examination may also relate to long-term patterns over
several screening rounds.
The main purpose of this study was to estimate the
cumulative probability of false positive mammography
tests and true positives in women’s visits with symptoms,
compared with those visits with no reported symptoms at
mammography screening in the Finnish programme in
women aged 50–69 years. In addition, we estimated the
risk of false positive test and true positive with accumu-
lated same symptom or any symptoms in the screening
history.
Materials and methods
Study design, setting, and data source
The current study is a register-based cohort study, which
utilizes the screening visit history of women who attended
the mammography screening program in Finland. The
program invited women aged 50–69 years every second
year for mammography screening in special organized
clinics. Information on breast cancer screening has been
registered at the Mass Screening Registry which is part of
the Finnish Cancer Registry. The women were asked about
breast symptoms at the visit. Any symptoms (lump,
retraction, secretion, mole, and scar) women had during the
past 2 months were recorded on the mammography form
(http://www.cancer.ﬁ/@Bin/44068785/Mammography?
form_2006.pdf). The mammography screening examina-
tion was two-view for both breasts. The detailed
mammography screening process has been described ear-
lier [5]. The registration coverage increased with time,
from 51.2 % in 1992 to 90 % in 1998 and virtually 100 %
in 2005 and afterwards [4].
The current study population included 413,611 women
who were invited for the ﬁrst time at age 50–51 years in
1992–2004 and were followed up until 2012. Altogether,
2,627,256 invitations were identiﬁed during the period
1992–2012, out of which 2,283,706 (87 %) visits were
made with an average of 5.5 visits per woman. Records
with missing data on symptoms were excluded from the
analysis (Table 1). The maximum number of visits per
woman was 10, and visits exceeding 10 (145 visits) due to
migration within the country were excluded from the cur-
rent analysis.
Deﬁnition of variables
Test positives are those with primary mammography pos-
itive—they are recalled for further assessment (often more
mammograms, ultrasound, and needle biopsy) at the
screening clinic, if the mammogram indicated any abnor-
mality. The assessment part is called an episode and those
with a positive episode are referred to hospital for diag-
nostics/treatment. Test positives may be episode negative
(no referral) or episode positives (referred) and those who
are then diagnosed with cancer are true positives at all
stages. False positive test are those with negative episode
or with a positive episode but no cancer diagnosis at hos-
pital. False positive mammography tests were further
classiﬁed as at least one or ﬁrst false positives depending
on the screening history: ‘at least one’ if a woman was
detected as false positive at any given screening visit
irrespective of earlier visit ﬁndings and ‘ﬁrst’ if a woman
was detected as false positive at any given screening visit
given that mammography in all previous visits was nega-
tive. False positive referrals are those with episode positive
but no cancer diagnosis in hospital. The average number of
visits per woman was deﬁned as the total number of visits
made at ages 50–69 years divided by the number of women
screened during that period of age. Number of invitations
per woman was counted as the number of subsequent
invitations a woman received after the ﬁrst invitation at age
50–51 years.
Women with symptoms reported either by the woman
herself or by the radiographer were considered as symp-
tomatic. Symptoms history variable for either lump or
retraction or secretion, was created and deﬁned as symp-
toms reported ever before or at the index visit. Here, index
visit means the visit that resulted in a positive test result
(either false positive test or true positive test). The possi-
bility of reporting more than one symptom at a single
screening visit was also considered. For that, combinations
of two symptoms at a time were made as ‘none,’ ‘either’
and ‘both.’ Separate variables for each symptom reported
once or more than once in the screening history were
created and coded as ‘1 time’ and ‘more than 1 time.’ A
separate variable on the absolute number of visits (1–10)
per woman was created to compare the probability of false
positive test by screening visits, overall versus those with
symptoms history.
306 Breast Cancer Res Treat (2016) 159:305–313
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Statistical analysis
Lump, retraction, and secretion, the most clinically rele-
vant symptoms, were used for analysis. Let i be the index
subjects i = 1,…, n and j be the index visits of ith subject
j = 1,…, Ji. We note by P(Yij = 1; Xij) the probability of a
false positive test for subject i at the jth screen given
covariates Xij. The cumulative risk of ﬁrst outcome event
after k rounds of screening is qk ¼ 1
Qk
j¼1 1 PðYij ¼

0; Yi j1ð Þ ¼ 0; . . .; Y1 ¼ 0Þg [8]. Applying discrete-time
hazard model with logit PðYijÞ
  ¼ X 00ijb an estimator for
cumulative risk can be obtained. A standard logistic
regression can be used to get an estimate of the logistic
regression model parameters. Suppose that subject i had
symptoms at the lth attended visit. For each subject i the
visits can be divided into non-symptomatic j = 1,…, l-1
visits and symptomatic visits j = l,…, J starting from the
ﬁrst symptomatic visit: yij;Xij ¼ 0
 
; i ¼ 1; . . .; I; j ¼
1; . . .; l 1g and yij;Xij ¼ 1
 
; i ¼ 1; . . .; I; j ¼ l; . . .; J .
Cumulative risk of false positive test and true positive
(cancer diagnosis) was estimated as shown above. General-
ized linear regression (GLM) model in R statistical software
was used to estimate the effect of an individual symptom as
well as combined symptoms on the false positive and true
positive probabilities. Conﬁdence intervals at 95 % were
estimated using approximateBayesian inference (INLA) [9].
Results
In 56,805 (2.5 %) visits at least one symptom was reported
during the study period in 1992–2012 with a maximum
follow-up of 21 years. A lump was reported in 26,145
(1.22 %) visits, retraction in 26,653 (1.59 %) visits, and
secretion was reported in 5325 (0.24 %) visits (Fig. 1).
There were combined symptoms, as well, with both lump
and retraction at 557 visits, lump and secretion at 572
visits, and retraction and secretion at 207 visits. Overall,
48,873 visits (2.1 %) out of total visits had false positive
tests. Of these, 44,541 false positive tests were conﬁrmed
one time and 4332 false positive test were conﬁrmed more
than one time in women screening history. The false pos-
itive test percentage at a given visit was 7.2 % (4063 visits)
in women with symptoms compared to 2.0 % (44,810
visits) in women with no symptoms. Similarly, the true
positive (breast carcinoma) percentage was 2.2 % (1230
visits) in women who reported symptoms compared to
0.4 % (9718 visits) in women with no symptoms (Fig. 1).
The percentage of women who reported a lump or
secretion was higher in younger age groups compared to
the older age groups (lump = 1.71 vs. 0.78 %; secre-
tion = 0.32 vs. 0.04 % at 1st and 10th visit, respectively)
(Table 1). The false positive proportion among women
who reported any symptoms was signiﬁcantly higher at
every visit (order, 1–10) compared to those who did not
report any symptoms, overall 7.2 vs. 1.5 %, respectively.
False positive test probability based on the absolute num-
ber of woman’s visits showed similar difference in women
with symptom history compared to women with no history
of symptoms (Fig. 2). However, false positive test proba-
bility was lower in women who had less (absolute) number
of visits compared to those who had completed all possible
(ten visits) screening visits. Similarly, the false positive
referral and true positive proportions were higher among
women who reported symptoms versus no reported symp-
toms, 2.8 vs. 0.6 % and 2.2 vs. 0.4 %, respectively.
Fig. 1 Flow diagram of mammography screening program by symptom status
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Table 2 shows the at least one cumulative false positive
test and true positive probability after 10 visits. The cumu-
lative probabilities of at least one false positive test, false
positive referral, and true positive were 18.2, 1.5, and 5.7 %,
respectively, after 10 visits. The cumulative probability of
ﬁrst false positive test was 15.9 % (not shown in Table).
The cumulative probability of having at least one false
positive test was signiﬁcantly higher in those who had a
history of lump compared to those with no history of lump,
45.2 vs. 17.2 % estimated for 10 visits. Cumulative proba-
bility of at least one false positive referral and true positive in
women who reported any symptoms in screening history
Fig. 2 False positive (FP) test probability; overall (i) and any symptoms (ii), by attended number of screening visits of women
Table 2 Cumulative probability of at least one false positive (FP) test, FP referral, and true positive after 10 screening visits
Screen
number
FP test
probability
Cumulative FP test
probability
FP referral
probability
Cumulative FP referral
probability
True-positive
probability
Cumulative probability of
true-positive
1 0.0407 0.0407 0.0034 0.0034 0.0047 0.0047
2 0.0216 0.0614 0.0014 0.0048 0.0037 0.0084
3 0.0187 0.0790 0.0013 0.0061 0.0042 0.0125
4 0.0167 0.0944 0.0010 0.0071 0.0045 0.0170
5 0.0159 0.1089 0.0010 0.0081 0.0053 0.0222
6 0.0154 0.1226 0.0011 0.0092 0.0060 0.0281
7 0.0149 0.1357 0.0011 0.0103 0.0065 0.0344
8 0.0141 0.1479 0.0010 0.0113 0.0069 0.0411
9 0.0174 0.1627 0.0015 0.0128 0.0076 0.0483
10 0.0224 0.1822 0.0024 0.0151 0.0090 0.0569
Bold numbers indicate the ﬁnal cumulative number
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were 3.8 and 12.6 %, respectively, compared to 1.4 and
5.3 %, in women with no history of any symptom. (Table 3)
There was some increase in the probability of false positive
test before the visit with a lump compared to visits with no
lump, though true positive probability did not differ (see
supplementary table, S1). Women who reported lump or
secretion more than one time had higher cumulative proba-
bility of at least one false positive test than women who
reported lump or secretion once in screening history, 47.8 vs.
44.0 % for lump and 39.8 vs. 33.4 % for secretion, respec-
tively. However, cumulative probability of true positive was
lower in women who reported symptomsmore than one time
compared to one time in screening history.
The cumulative false positive probability in women who
reported ‘lump and retraction’ was higher, 56.5 % (95 % CI
47.4–66.3) compared to those who did not report either
symptom, 17.1 % (95 %CI 16.6–17.7) (Fig. 3). ForWomen
who reported ‘lump and secretion, the cumulative false
positive test probability was 54.8 % (95 % CI 45.3–69.6).
Discussion
Our study found signiﬁcantly higher cumulative false
positive test and true positive probability among those who
reported symptoms at screen compared to those who did
not report any symptoms. The cumulative risk of false
positive test (after 10 rounds) with any symptom was 38 %
and that without was 17 %. Lump was associated with the
highest cumulative false positive risk of 45 %, retraction
25 %, and secretion 35 %.
The overall cumulative probability of at least one false
positive test was 18 % after 10 screening visits at age
50–69 years and the false positive test probability was
3.6 % at the ﬁrst visit at age 50–51 years. Our results are
consistent or somewhat lower with that of previous studies
from other European countries [10–17]. A study from
Norway reported a higher cumulative false positive risk
(23 %) than the current study [10]. Another study esti-
mated a 21 % cumulative false positive probability pro-
jected after 10 screening visits, based on the results of three
consecutive screening visits performed in four counties
[11]. A retrospective cohort study from Spain projected the
cumulative false positive risk to be 20.4 % after 10
screening visits [12]. Cumulative false positive probability
from a randomized trial in the UK (2010) was 20.5 % over
seven screening rounds [16]. A Danish study [14] made the
prediction, based on 3–5 observed screening rounds, of
cumulative false positive test probability slightly lower
than that of our study. However, the false positive test
probability at ﬁrst screen was higher (5.7 %) in Copen-
hagen than that of the current study. In the Netherlands,
Otten et al. (2013) found lower cumulative false positive
risk after 13 consecutive screening examinations than that
of our study, but they expected higher estimates after
digital mammography was introduced in 2003 [18, 19].
Nonetheless, there were some variations between countries
in the methodology and health service system, such as age
at ﬁrst invitation [10, 14, 18], projected estimates based on
few observed rounds [11, 18], and lower recall proportion
of\1 % at subsequent screens [18, 20] compared to 2.2 %
in our study and\3 % in European guidelines [21], while
estimating the false positive risk.
Studies conducted in the USA have reported much
higher risk of cumulative false positive tests than that of the
current study [8, 22–25]. In the US, Breast Cancer
Surveillance Consortium (BCSC) data from all women
(n = 88,455) ﬁrst screened at age 50-69 years between
1996 and 2010 estimated the cumulative false positive risk
to be 41.9 % after eight screens annually or biennially [24].
The reason for lower estimates in our study may be due to
different program organizations in Finland than in USA as
well as variation in age at ﬁrst screening, deﬁnitions of
recall, recording and coding of screening data, screening
interval, etc. [26]. Also, the European quality standards
[21] are adequately met by the Finnish screening program.
Together with the cumulative probability of ‘at least
one’ false positive, this study also estimated the cumulative
‘ﬁrst’ false positive test and true positive probability. The
Table 3 Cumulative probability of at least one false positive (FP)
test, FP referral, and true positive in women with a history of
symptoms
Symptoms
history
Cumulative
probability
of false
positive test
Cumulative
probability of
false positive
referral
Cumulative
probability of
true positive
Lump
Yes 0.4516 0.0332 0.1630
1 time 0.4401 0.0357 0.2002
[1 time 0.4780 0.0268 0.0650
No 0.1721 0.0146 0.0531
Retraction
Yes 0.2464 0.0261 0.0903
1 time 0.2662 0.0429 0.1868
[1 time 0.2342 0.0159 0.0368
No 0.1807 0.0204 0.0567
Secretion
Yes 0.3477 0.0789 0.0638
1 time 0.3339 0.0677 0.0691
[1 time 0.3981 0.1239 0.0489
No 0.1811 0.0146 0.0569
Any symptom
Yes 0.3843 0.0377 0.1262
1 time 0.3938 0.0422 0.1730
[1 time 0.3694 0.0315 0.0533
No 0.1699 0.0138 0.0530
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cumulative ﬁrst false positive probability was 16 % as we
considered only the ﬁrst false positive mammography
result, excluding later false positive ﬁndings of the same
woman. Hence, the estimate is lower than the ‘at least one’
false positive estimate. Also, the lower probability of false
positive in our study may be due to the exclusion of the ﬁrst
visits made at later age, hence removing contamination of
newcomers at later visits with prevalent screens. Our study
estimated the cumulative true positive probability to be
6 % after 10 screening visits. A study in the Netherlands
estimated similar cumulative cancer detection risk after 13
consecutive screening examinations [18]. We are not aware
of other studies on cumulative true positive estimates after
10 screening visits.
No prior studies have estimated the cumulative proba-
bility based on reported symptoms with a complete follow-
up information. Women who reported having symptoms,
especially lump and secretion at screening visit, current or
at any previous visit, were signiﬁcantly more likely to have
a false positive test and true positive result than women
with no symptoms reported. The cumulative false positive
probability in women with a history of lump was 45 %
compared to 17 % with no lump. When considering the full
visit history of women with lump, before and after visit
with lump, the higher probability of false positive test
before the visit with a lump indicates that there was a
possibility that some unspeciﬁc changes in the
mammograms had been seen even several years before the
visit when a lump was reported. On the other hand, after
reporting the ﬁrst symptom there was no increase in the
probability of false positive test and true positive results in
the later visits. This means that woman was treated and no
cancer was detected in later visits. Women were more
likely to be true positive if they reported symptoms at
screen; cumulative true positive probability of 16 % was
compared to 6.5 % with no reported lump. Similarly,
women who reported both ‘lump and retraction’ in the
same visit had cumulative false positive test probability of
56.5 % (95 % CI 47.4–66.3) compared to 17.1 % (95 % CI
16.6–18.3) without symptoms. Similar results were found
in women with other possible combination of symptoms.
Taking into account the information on breast symptoms,
there is a concern for the radiologist whether or not to
recall the symptomatic women. Also, variation in the false
positive probability by symptom status, number of times
symptom was reported, shows that not all symptoms are
equally sensitive. At the same time, the ﬁndings also
showed beneﬁts of evaluating symptoms information on
the performance (more cancers detected) of mammography
screening program.
One of the limitations of this study is the missing
information on some important risk factors such as hor-
mone use, breast density, and family history of breast
cancer, while estimating the cumulative false positive and
Fig. 3 Cumulative probability of at least one false positive (FP) test among women reported symptoms at screen
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true positive probability in relation to symptoms. The
missing information (1.2 % of total visits) on symptoms
was due to incomplete reporting by some centers in the
early years of the program. Women recalled but not
referred to hospital and women referred but with no cancer
in histological conﬁrmation who may have had a cancer
before the next screening visit (interval cancer), were not
taken into account in this study. Other performance mea-
sures of screening program, including interval cancers and
mortality as stated by Otten et al. [18] and Tornberg et al.
[27], in relation to breast symptoms need to be evaluated
thoroughly.
The current study is based on a large nationwide
screening cohort with complete follow-up of the women
up to maximum 10 visits (21 years). The high partici-
pation rate ([85 %) in the screening program and few
opportunistic screening means false positive probability
estimates over the 10 screens equals the lifetime risk of
false positive test in Finland, which is similar to that
reported by a Danish study [14]. The radiologists
learning of the previous mammography results and the
small difference between ‘at least one’ and ‘ﬁrst’
cumulative probability estimates form the basis to con-
clude independence between false positive risks at sub-
sequent screen.
In conclusion, the current study showed that information
about breast symptoms, especially lump, cause harms in
terms of extra false positive ﬁndings. The risk varies sub-
stantially, depending on symptom types and characteristics.
At the same time, more cancers were detected in symp-
tomatic women suggesting beneﬁts of evaluating symptoms
information in the program. Information on breast symp-
toms inﬂuences the balance of absolute beneﬁts and harms
of screening for the individual woman, and should be
considered carefully in breast cancer screening programs.
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Association of symptoms and interval breast cancers in the
mammography-screening programme: population-based
matched cohort study
Deependra Singh1,2, Joonas Miettinen1, Stephen Duffy3, Nea Malila1,2, Janne Pitkäniemi1 and Ahti Anttila1
BACKGROUND: We assessed the association between symptoms reported at breast cancer screening visits and interval cancers
(ICs) in a prospective manner.
METHODS: This population-based matched cohort study uses data of the Finnish National Breast Cancer Screening Programme
that invites women aged 50–69 years old during 1992–2012. Subjects who attended screening with symptoms were matched with
asymptomatic reference cohorts based on age at screening visit, year of invitation, number of invited visits and municipality of
invitation. The primary outcome was ICs.
RESULTS: Women with a lump had a threefold (hazard ratio 3.7, 95% conﬁdence interval (CI) 3.0–4.6) risk of ICs and a higher risk
(hazard ratio 1.7, 95% CI 1.4 to 2.0) at the subsequent visit compared with those without a lump. The fatal interval cancer risk
increased by 0.39 per 1000 screens with a lump. The cumulative incidences of interval cancer increased within a month of a
mammography-negative visit with a lump and after about 6 months of the visit with retraction or nipple discharge.
CONCLUSION: Women with breast symptoms have a clearly increased risk of interval breast cancer after the screening visit. Our
ﬁndings indicate the need for different screening strategies in symptomatic women.
British Journal of Cancer (2018) 119:1428–1435; https://doi.org/10.1038/s41416-018-0308-2
BACKGROUND
Beyond the randomised trial environment, there is some
uncertainty as to the underlying incidence of breast cancer and
the rate of overdiagnosis in the screening population.1,2 Along
with screening performance,3–5 rates and proportions of interval
cancers (ICs) are important indicators for assessing the effective-
ness and quality of screening.2,6–8 The substantial proportion
(about a third) of incident breast cancer diagnosed outside the
mammography-screening programme9,10 likely indicates that
there is room for improvement in the detection capability of the
mammography-screening programme. Earlier observational stu-
dies7,11–15 have highlighted several reasons for the increased
proportion of ICs in the screening programme. However, in terms
of equity within the screening population, it is reasonable to aim
for similar interval cancer rates or at least similar proportions of
cancers arising as interval cases for the various heterogeneous
groups participating in the screening. Furthermore, options to
modify screening policies should be considered for high-risk
groups. A shorter screening interval may be justiﬁed, for instance,
if the interval cancer rate is signiﬁcantly high.
Based on the European Union (EU) guidelines, screening is
meant for unselected target population.7 Earlier studies from
Finland have indicated that a noticeable proportion (~ 2–3%) of
women have clinically signiﬁcant symptoms when they participate
in breast cancer screening.16,17 Most but not all symptomatic
women will have further assessments with ultrasound, additional
mammograms or other methods; if these return negative results,
the women return to the normal, biennial screening interval.
Studies on breast symptoms (such as a lump, retraction or nipple
discharge) indicate an increased risk of breast cancer16–19 at the
cost of rise in false-positive ﬁndings. The relations of symptoms
with interval breast cancers and screen-detected cancers (SDCs) at
the subsequent visit have never been studied.
We investigated whether women reporting breast symptoms at
screen are at a higher risk of developing subsequent breast
cancers (ICs and cancers diagnosed at the next screen) than those
without symptoms. To create foundations to modify the screening
policies in high-risk groups, we estimated the cumulative
incidence of ICs and fatal interval breast cancers, and compared
the respective incidences in women with and without symptoms.
The quality measures of screening mammography were compared
between visits among subjects with and without symptoms to
gather evidence for improving programme performance.
METHODS
Study design, data source and study population
Our matched cohort study design was based on the follow-up of
the ongoing Finnish National Breast Cancer Screening Programme
that began in 1987. Biennial screening visits made by women
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aged 50–69 years between 1991 and 2012 were selected. Three
registries, the Finnish Cancer Registry (1953–2014), the Mass
Screening Registry (1992–2012) and the Central Population
Registry (1992–2014) were used to extract information on the
study participants at the individual level. The Mass Screening
Registry was used to extract information on demographic,
symptomatic and screening procedure factors, including recalls
and referral data that have been shown to be valid and of high
quality. All individual visits were linked to the Finnish Cancer
Registry database to retrieve information on breast cancers
(screen-detected and ICs). This included histological ﬁndings and
potential death from incident breast cancer. The Population
Registry was used to identify possible dates of death or
emigration, and where applicable, the cause of death was
retrieved from Statistics Finland. Fig. 1 shows the ﬂow diagram
of the study design.
Exposure group (screening visits with symptoms)
The exposed group is deﬁned as visits by women with breast
symptoms (lump, retraction and nipple discharge) reported at a
given screening round. This group contained all visits with at least
one symptom reported. Different symptoms (lump, retraction,
nipple discharge) were analysed separately, which in technical
terms assumes that the ﬁrst occurrence of any symptom was
independent given the covariates. For example, if more than one
symptom was reported at a single visit then each symptom was
analysed separately. Here, the index visit meant any screening visit
with any given symptom.
Reference group (screening visits without symptoms)
The reference group is deﬁned as visits by women with no
reported breast symptoms in the screening history before the
index visit. The women from the reference group can later be the
part of the exposed group if symptoms are reported at future
screening visits. Thus, symptoms are time-dependent covariates.
Individual sets of reference visits for each symptom—altogether
three sets—were formed by matching.
Matching
The three exposed groups were frequency matched to the
reference groups by age at the screening visit (within 2 years),
year of invitation (2-year band), number of visits in the past and
municipality of invitation. Visits with symptoms were then
aggregated based on matching variables (and other covariates).
Each symptom stratum was matched to the viable controls
(reference visits) by random sampling. Random controls were
selected, based on the matching variables above, as many times
as the number of visits in each stratum of symptoms by the
replacement sampling method. Hence, a single control had the
possibility to be randomly selected more than once to the same
stratum. Based on our assumption of an effect size and required
power of 0.80, the exposed-to-reference-visits ratio was 1:1 for
lump and retraction, and 1:2 for nipple discharge.
Outcome assessment
ICs were deﬁned as breast cancers diagnosed in screened women
before the next screening visit or within a period equal to a
screening interval with (i) negative mammography at the index
visit (i.e., test negative); (ii) positive mammography at the index
visit, but negative further assessment (i.e., episode negative); and
(iii) positive further assessment but a date of diagnosis > 6 months
after mammography.2 SDCs were deﬁned as primary breast cancer
diagnosed among the screening attendees within 6 months
following an abnormal mammogram (test positive). The subse-
quent round SDCs were analysed following the index visits with or
without symptoms if the women attended the subsequent round.
Finnish national breast cancer screening program (FNBCSP)
Mass screening registry
(1992-2012)
Information on the
mammography
screening process,
includes symptoms
information
Information on
cancers, screen-
detected and interval
cancers, and fatal
breast cancers
222848 visits
excluded because of
missing information
on symptoms status Visits with symptoms
(exposure group)
Lump = 51333
Retraction = 40917
Nipple discharge = 9083
Visits without symptoms
(reference group)
No lump = 51332
No retraction = 40917
No nipple discharge = 18166
Matching*
Exposure group were frequency
matched to reference group
(visits without symptoms) by
covariates, selected by random
sampling using replacement
method
Population registry
(1992-2014)
Invited for screening
(4,594,335)
Attended (3,958,312)
*1:1 matching ratio for lump and retraction, 1:2
ratio for nipple discharge
Study population
(3,735,464)
Cancer registry
(1992-2014)
Fig. 1 Flow diagram of study settings
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In addition, cancers were sub-grouped into in situ carcinomas and
non-localised breast cancers. Fatal cancers were deﬁned as those
breast cancers that resulted in death during follow-up.
Follow-up
The follow-up time started from the index visit in 1 January 1992
to 31 December 2012 and ended at the date of emigration or
death, upon diagnosis of interval cancer or at the end of the
follow-up—i.e., 31 December 2014—whichever occurred ﬁrst.
Cancer cases diagnosed among those screened up to 31
December 2012 and followed up to 31 December 2014 (for those
screened in 2011 and 2012) were divided into ICs and subsequent
SDCs using Finnish Cancer Registry data. Considering possible
delays in the diagnosis date after positive mammography ﬁndings,
a screening episode of 6-month intervals was used in the
deﬁnition of detection mode. Thus, the follow-up time for ICs
started at 7 months for episode negative visits and at 1 month for
test negative visits and ended at the date of the subsequent
screening visit at 23 months.
Statistical analysis
We compared breast cancer risk and the risk of breast cancer
death using Cox proportional hazard regression among women
with and without reported symptoms at the index screen.
Conﬁdence intervals were computed exactly from parameter
likelihoods. The analyses were adjusted for age at the screening
visit. We calculated the incidence rate of interval cancer between
the screens (from the index screen and the 6-month episode to
the subsequent screening visit) separately for test negatives and
episode negatives.
We also evaluated the programme characteristics using basic
statistics. A test sensitivity was estimated as the number of visits
with a positive mammography test and diagnosis of cancer at
screen divided by the sum of SDCs plus ICs diagnosed after
negative test results. Episode sensitivity was calculated as the
number of visits with a diagnosis of cancer in a full diagnostic
process in the screened population divided by all cancers
detected in a screening round among attenders. Similarly, the
positive predictive value (PPV) was assessed as the number of
visits with a positive mammography test and diagnosis of cancer
divided by the number of test positives. The negative predictive
value (NPV) was estimated as the number of visits with a negative
test result and no cancer diagnosed divided by the number of test
negatives. All statistical analyses were performed using R-3.4.0.
RESULTS
Over the study period of 21 years, a lump was reported at 51,333
visits and retraction at 40,917 visits. These visits were matched to
an equal number of asymptomatic visits. There were 9083 visits
with nipple discharge, and they were matched with double the
number of reference visits (i.e., 18,166 visits) without nipple
discharge. Detailed numbers of the potentially eligible and the
conﬁrmed eligible population included in the study are shown in
Fig. 1.
The mean age at a screening visit did not differ between visits
with and without symptoms (mean age 55.7 vs 56.1 years for visits
with and without a lump, respectively). Table 1 shows the
characteristics of the ﬁnal study cohort. About one in three
women who reported a lump or nipple discharge and one in eight
women who reported retraction were ﬁrst-time attendees. The
ﬁrst and subsequent attendee’s proportions were similar between
visits with and without symptoms. More than 80% of ICs and the
subsequent round’s SDCs, irrespective of reported symptoms
status, were not recalled for further assessment at the index visit.
Both the test and episode sensitivity of the mammography was
higher for visits with a lump or retraction compared with those
without such symptoms (82 and 75% vs 64 and 63% for a lump vs
no lump; 77 and 76% vs 67 and 66% for retraction vs no retraction;
Table 2). Likewise, the PPV of mammography was higher for
retraction and a lump, compared with those without these
symptoms. However, the speciﬁcity of mammography was clearly
lower for visits with a lump (88%) than those without (98%). Some
decrease in speciﬁcity was also seen for retraction and nipple
discharge.
Incidence of screen-detected and ICs, subsequent SDCs and fatal
ICs
In total, 1440 (2.8%) SDCs and 387 (0.7%) ICs (ICs) were diagnosed
in those who reported a lump compared with 174 (0.3%) SDCs and
103 (0.2%) ICs in those without a lump, respectively (Table 3). The
proportions of SDCs and ICs were higher also for retraction and
nipple discharge compared with those without these symptoms.
The age-adjusted risk of SDCs was signiﬁcantly higher in those
who reported a lump (adjusted hazard ratio 8.2, 95% CI 7.0–9.7),
retraction (adjusted hazard ratio 2.3, 95% CI 2.0–2.8) or nipple
discharge (adjusted hazard ratio 1.5, 95% CI 1.1–2.3) compared
with those without symptoms. In addition, the age-adjusted risk of
ICs was signiﬁcantly higher for a lump (adjusted hazard ratio 3.7,
95% CI 3.0–4.6), retraction (adjusted hazard ratio 1.5, 95% CI
1.1–1.9), and nipple discharge (adjusted hazard ratio 2.4, 95% CI
1.6–3.7) compared with those without these symptoms. The risk of
SDCs in the subsequent round was signiﬁcantly higher only after
visits with a lump compared with those without a lump (adjusted
hazard ratio 1.6, 95% CI 1.3–2.0). The risk of in situ interval
carcinomas or subsequent screen-detected carcinomas was also
higher in visits with a lump and nipple discharge compared with a
visit with no symptoms. The risk of non-localised interval breast
cancer as well as SDCs in the subsequent round were also greater
for all three symptoms in comparison with visits without
symptoms.
The age-adjusted risk of dying from breast cancer was
signiﬁcantly higher in those who reported a lump and were
diagnosed with invasive cancers (SDCs= adjusted hazard ratio 19,
95% CI 11–38; ICs= adjusted hazard ratio 2.0, 95% CI 1.1–3.4;
subsequent round cancers= adjusted hazard ratio 2.7, 95% CI
1.6–4.1) compared with those without a lump (Table 3). In
addition, the risk of dying was higher in those who reported
retraction and were diagnosed with SDCs (adjusted hazard ratio
6.3, 95% CI 2.8–16) compared with those without retraction. Only
a few deaths occurred during the follow-up in those who reported
nipple discharge.
Cumulative incidence of breast cancers during the screening
interval
The incidence of ICs after a visit with a lump or nipple discharge
increased rather rapidly after the visit in all the studied
progression types (Fig. 2 a–d). When using the cumulative
incidence of the asymptomatic over the whole interval as a
reference, the same level of ICs was reached in only about six
months after visits with a lump and 12 months after visits with
nipple discharge. Remarkably, in mammography-negative visits
with a lump, the cumulative incidence curve detached from the
no lump curve immediately after the ﬁrst month of visit, whereas
such a difference was not observed for the other symptom types.
DISCUSSION
In this population-based study with 21 years of screening (the
follow-up is restricted to 23 months, although the study period
was 21 years), we observed strong associations between
symptoms and breast cancer risks. Women reporting a lump at
a screening visit had a threefold risk of ICs compared with those
with no symptoms, also including subsequent SDCs. The
(cumulative) incidence of interval cancer was higher in those
who reported a lump irrespective of the mammography ﬁndings
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(test negatives or episode negatives) compared with those
without symptoms at the index visit. Likewise, retraction and
nipple discharge were signiﬁcantly associated with increased risks
of interval breast cancers. In absolute terms, per 1000 women who
attended and reported a lump, seven women were diagnosed
with invasive interval breast cancers, i.e., within 24 months
compared with about two cancers diagnosed without symptoms.
The fatal interval cancer risk increased by 0.39 per 1000 screens
with a lump.
Women with symptoms had a clearly increased ‘background’
risk of breast cancer; the conventional screening performance
measures—such as sensitivity, PPV and speciﬁcity—did not fully
assess this aspect. The cumulative incidence patterns as well as
the detection of cancers during the subsequent round provided
direct evidence of the need for risk-adjusted screening and a
better diagnostic work-up in the symptomatic women. The
diagnostic work-up could include developing better reading and
recall criteria in screening mammograms, a more detailed
Table 2 Performance quality measures of screening mammography in relation to symptoms status
Symptoms Screening episode Mammography test
Sensitivity % (95% CI) Sensitivity % (95% CI) PPV % (95% CI) NPV % (95% CI) Speciﬁcity % (95%CI)
Lump Yes 74 (71–78) 81 (80–83) 19 (19–20) 99 (99–99) 88 (88–88)
No 62 (56–68) 64 (58–70) 12 (11–13) 99 (99–99) 97 (97–97)
Retraction Yes 75 (72–79) 76 (73–80) 28 (26–29) 99 (99–99) 97 (96–97)
No 65 (59–70) 66 (60–72) 17 (16–19) 99 (99–99) 97 (97–98)
Nipple discharge Yes 55 (46–65) 62 (52–71) 8.1 (6.9–9.4) 99 (99–99) 91 (91–92)
No 66 (57–75) 70 (61–78) 15 (13–17) 99 (99–99) 97 (97–97)
PPV positive predictive value, NPV negative predictive value, CI conﬁdence interval
Table 1 Cohort characteristics
Characteristics Lump (n= 51,333) Retraction (n= 40,917) Nipple discharge*
Yes (%) No (%) Yes (%) No (%) Yes (%)
(n= 9083)
No (%)
(n= 18,166)
Age at index visit (mean, SD) 55.7 (4.6) 56.1 (4.5) 57.7 (4.9) 56.6 (4.8) 54.9 (4.6) 56.1 (4.7)
Attendance First attendance 18,305 (35) 17,954 (35) 5012 (12) 4959 (12) 2904 (32) 5643 (31)
Subsequent attendance 33,028 (64) 33,379 (65) 35,905 (87) 35,958 (87) 6179 (68) 12,523 (68)
Previous round
attendance
Yes 31,571 (61) 32,228 (62) 34,168 (83) 34,263 (83) 5842 (64) 12,069 (66)
No 19,762 (38) 19,105 (37) 6749 (16) 6654 (16) 3241 (35) 6097 (33)
Period of visit 1992–1997 15,478 (30) 15,520 (30) 0 0 1134 (12) 2298 (12)
1998–2002 7535 (14) 7493 (14) 3552 (8.7) 3552 (8.7) 1673 (18) 3316 (18)
2003–2007 11,791 (23) 11,804 (23) 12,996 (31) 13,190 (32) 2872 (31) 5671 (31)
2008–2012 16529 (32) 16,516 (32) 24,369 (59) 24,175 (59) 3404 (37) 6881 (37)
Recall (test positives)
Invasive cancers Screen-detected cancers 1440 (2.8) 174 (0.34) 461 (1.1) 192 (0.47) 66 (0.73) 83 (0.46)
Interval cancers 70 (0.14) 7 (0.01) 16 (0.04) 5 (0.01) 12 (0.13) 6 (0.03)
Subsequent screen at next
round
34 (0.07) 6 (0.01) 11 (0.03) 7 (0.02) 4 (0.04) 3 (0.01)
Fatal breast cancers Screen-detected cancers 215 (0.41) 11 (0.02) 38 (0.09) 6 (0.01) 4 (0.04) 2 (0.01)
Interval cancers 8 (0.01) 2 (0.01) 2 2 0 0
Subsequent screen at next
round
1 (0.01) 0 1 (0.01) 0 0 0
No recall (test negatives)
Invasive cancers Screen-detected cancers 0 0 0 0 0 0
Interval cancers 317 (0.62) 96 (0.19) 138 (0.34) 96 (0.23) 40 (0.44) 35 (0.19)
Subsequent screen at next
round
230 (0.45) 149 (0.29) 144 (0.35) 135 (0.33) 28 (0.31) 57 (0.31)
Fatal breast cancers Screen-detected cancers 0 0 0 0 0 0
Interval cancers 32 (0.06) 18 (0.03) 13 (0.03) 5 (0.01) 5 (0.05) 2 (0.01)
Subsequent screen at next
round
18 (0.03) 7 (0.01) 4 (0.01) 4 (0.01) 0 1 (0.01)
Values are numbers (percentage) unless stated otherwise
*For each visits with nipple discharge were matched with two visits without nipple discharge
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indication for biopsies in the further assessment, and early recall
for those with high-risk symptoms for whom the screening test or
further assessment proves negative.
Strengths and limitations of the study
To our knowledge, this is the ﬁrst population-based study to
analyse the association between symptoms and interval and fatal
breast cancers. Our study has several strengths. First, we included
all screening visits with symptoms from the start of the
mammography-screening programme (over 21 years) and com-
pared them with visits without symptoms. Since this was a
population-based service-screening programme, the selection bias
was minimal. Second, we could use validated prospectively
collected register data with no recall bias.20 Validation of the
cancer diagnosis (screen-detected and ICs) and death from cancer
using national and covering data sources (Finnish Cancer Registry
and Statistics Finland) and the use of unique personal identiﬁer for
individual-level linkage eliminates the possibility of selective
misclassiﬁcation. Third, we matched the symptomatic visits to
asymptomatic visits by possible confounding baseline character-
istics to minimise bias in the risk estimates. As a result, we found
no signiﬁcant difference in the background variables between
visits with and without symptoms. Finally, the programme process
and outcome indicator deﬁnitions used in this study adhere to
those deﬁned by WHO-IARC and mentioned in EU guidelines on
breast cancer screening and diagnosis,7,21 including the provision
of relevant information describing the performance and also
failures during the various steps of the screening process.
Our study also has potential limitations. The symptom informa-
tion was based on the women’s reporting in the past 2 or
6 months and a check by a radiographer at the visit. The
radiographer’s inspection is likely to be less comprehensive than a
full clinical examination. The collection of symptom information
is mainly done in order to support the interpretation of the
mammograms. However, in almost every case—if not all—the
radiographer or nurse examines the breast to conﬁrm
the presence of symptoms (mainly a lump and retraction) before
the mammography is performed. Thus, there are reasons to
consider the collected symptom information to be valid, albeit not
perfect. A second potential limitation is that our estimates could
have been confounded, because symptomatic women are more
likely to attend than asymptomatic women. However, because of
the high attendance rate in the Finnish mammography-screening
programme (84% among the invited, the highest among any
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existing mammography-screening programme), and as 97% of
attendees are asymptomatic, the attendance bias caused by
symptoms is likely to be small. Third, we did not use the
background incidence of breast cancer to estimate the interval
cancer rate in the absence of screening, but instead used a
detection method22 that takes into account cancers from the
screening programme; thus, estimates are sensitive to over-
diagnosis and lead time bias. Given the high coverage and
attendance rate in the Finnish screening programme, it was not
possible to ﬁnd a comparable non-screened group to estimate the
background incidence of breast cancer. In addition, there was no
possibility to estimate background incidence of breast cancer in
women with symptoms. We did not ﬁnd any difference in the PPV
of mammography, with and without symptoms, between the ﬁrst
and subsequent screening rounds (not shown in results); thus, the
lead time bias because of prevalent screens is negligible.
Furthermore, we used invasive breast cancers—and also
advanced and fatal breast cancers, which would be less affected
by overdiagnosis—to estimate the incidence rates and hazard
ratios. Only 5% of all carcinomas in those with symptoms were
in situ carcinomas.
Previous studies on the association between symptoms and the
risk of breast cancer are limited because of factors such as study
design, size, follow-up time and assessment of the possible
outcome measures of breast cancer. Nonetheless, a few studies
have found that the presence of a palpable lump is associated
with a higher risk of SDCs.18,19 We are not aware of any studies
that have assessed the relationship of symptoms with other
outcome measures.
Clinical and public health implications
Both the screening test and episode sensitivities tended to be
higher in symptomatic women compared with the asymptomatic.
Correspondingly, the screening speciﬁcity was lower in the
symptomatic women. Of note, particularly in women with a lump,
were the (episode) sensitivity losses in the further assessment during
the index visits. Moreover, higher interval cancer incidence within six
months after a negative mammography with a lump is a clear
concern for the programme. This indicates that further assessment is
needed more frequently (albeit with a potential loss of speciﬁcity),
and there needs to be highly stringent diagnostic evidence for a
decision not to carry out a full further assessment including a core
biopsy in these cases. As most visits (~ 97%) were asymptomatic, the
number of additional services would be rather small as well as the
improvement of programme’s overall performance and outcome.
But still, high-quality and clinically appropriate services are
important for women having symptoms at a screening visit. One
option is to recall all women with symptoms even if the
mammography result is negative, as practised in Norway (< 0.3%
of all those screened were recalled with symptoms).23 Doing this in
Finnish programme would signiﬁcantly lower the PPV of recall, as
2.5% of all screens had symptoms and only ~ 1 out of 10 sympto-
matic visits have been recalled.17
Taking into account the high incidence of advanced and fatal
interval breast cancers in symptomatic women, it is likely that
protection by biennial screening visit would clearly not be
sufﬁcient even after potential improvements in further assess-
ments. We are not aware of recommendations for surveillance or
follow-up of symptomatic women in the programme. Hence, we
recommend a shorter screening interval for the symptomatic
group so that the cumulative incidences of interval and fatal
interval cancer would possibly become more equitable. For two of
the studied symptoms (lump and nipple discharge), the interval
cancer incidence increased so rapidly that the ﬁrst follow-up visit
could take place very shortly after the index visit. Finally, taking
into account the probability of fatal screen-detected breast cancer
is higher in women with a symptom already at the index visit,
women need to be better informed about symptoms and made
aware that if a symptom occurs, it is not a good idea to wait until
the next invitation to the programme. Guidelines for further
assessment in patients presenting with symptoms before having a
scheduled invitation according to the programme—as developed
by National Health Service in the UK24—could be useful also in
other settings.
CONCLUDING REMARKS
Women with breast symptoms at visits within the population-
based breast cancer screening programme have a clearly
increased risk of breast cancer. The cumulative incidence of
invasive, advanced and fatal breast cancers, as well as the
detection of them at the next screen, provide direct evidence for
the need for risk-adjusted screening in symptomatic women—
e.g., tailoring the management procedures at index visits and
shortening the screening intervals for these women. This study
provides clear evidence to update and support the EU guidelines7
recommendation that ensures sufﬁcient attention being paid to
symptomatic details provided by women. Our ﬁndings therefore
have important implications for screening-aged women, radiolo-
gists, nurses and mammography-screening programmes overall.
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Cancer incidence and mortality patterns in women with breast
symptoms in the mammography screening programme: A
matched cohort analysis
Deependra Singh 1,2, Nea Malila1,2, Janne Pitkäniemi1 and Ahti Anttila1
1Mass Screening Registry, Finnish Cancer Registry, Helsinki, Finland
2Epidemiology Group, Department of Health Sciences, University of Tampere, Tampere, Finland
Efforts to reduce mortality through early detection and diagnosis has intensiﬁed in the recent decade. An important risk factor,
‘breast symptoms’ reported by women during screening visit, remains overlooked. In this population based matched cohort study
using Finnish National Breast Cancer Screening Program (FNBCSP), we assessed the association between breast symptoms
reported at screening visit and the risk of cancer incidence and breast cancer mortality and all-cause mortality followed-up over a
period of 24 years. For each visit with symptoms, non-symptomatic controls were matched (1:1 for lump and retraction; 1:2 for
nipple discharge) based on age at screening visit, year of invitation, number of invited visits, and municipality of invitation.
Women who reported lump or retraction had about two-fold risk of breast cancer incidence, three-fold risk of breast cancer
mortality and all-cause mortality respectively as compared to women without respective symptoms (p-value<0.05). We found a
substantial difference (p-value<0.05) in mortality rates throughout the follow-up period between symptomatic and asymptomatic
group. In absolute terms, after the follow-up period for women who reported lump, 180 died from breast cancer as compared to
70 deaths in those without lump, per 10,000 person-years of follow-up, and 315 versus 160 all-cause deaths per 10,000 person-
years in women with and without lump respectively. our study provides comprehensive evidence that women with breast
symptoms remain in a higher risk of dying over a very long period. The ﬁndings indicate needs to develop improvements in the
guidelines for screening and clinical services for women presenting with symptoms.
Introduction
Based on the evidence supported by randomized controlled
trails and observational studies, World Health Organization,
in 2016 concluded that women attending mammography
screening have about 40% reduced risk of breast cancer mor-
tality.1 However, use of mammography screening remains
debated.2,3 Many studies have proposed personalized screen-
ing modalities based on important risk factors, such as family
history of breast cancer,4–6 breast density,7–9 and gene muta-
tion.10 An important risk factor, ‘breast symptoms’ reported
by clinical examination or by women during screening
visit, remains overlooked. The single reason is that many
population-based mammography-screening programmes have
not collected or analyzed information on breast symptoms. In
many programmes, on the other hand, most of the women
presenting with symptoms such as a lump, retraction, or nip-
ple discharge have further assessment, but are not systemati-
cally followed-up in the programme up to cancer diagnosis or
death.11,12 Also, the EU guidelines lack evidence on the risk of
breast cancer or mortality in those women.13
Recent studies from Finland showed sufﬁcient evidence
that information on symptoms collected at women’s mam-
mography visit, increases the risk of advanced stage breast
cancers.14,15 Higher advanced cancer risk might be correlated
with the higher risk of death from breast cancer. The relation
of symptoms, as adjunct to screening mammography, with
mortality have never been studied. Therefore, it is important
to quantify (or measure) the discrepancy, if any exists, in
mortality between women with and without symptoms.
Key words: breast cancer symptoms, cancer incidence, incidence-
based mortality, lump, screening strategy
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To address these uncertainties, we conducted a prospective
analysis of the association between breast symptoms reported
at screening visit and the risk of cancer incidence and mortal-
ity followed-up over a period of 24 years.
Materials and Methods
Study population
We conducted a matched cohort study using prospective data
of ongoing Finnish National Breast Cancer Screening Pro-
gramme (FNBCSP). Since the beginning of the programme in
1987 every women in the target population aged 50–69 years
are invited biennially for mammography screening.16 Individ-
ual level information of the study participants is extracted
using three registries, the Finnish Cancer Registry
(1953–2015), the Mass Screening Registry (1992–2012), and
the Central Population Registry (1992–2014). The study
cohort includes 3,735,464 screening visits made by women
during 1992–2012. Figure 1 shows the ﬂow diagram of study
settings and outcomes.
The exposure group (screening visits with symptoms)
includes women with reported breast symptoms (lump, retrac-
tion, and nipple discharge) at a given screening visit. This
group contained ﬁrst symptomatic visit with at least one
symptoms. Symptoms are analyzed separately meaning that
ﬁrst occurrence of any given symptom was independent of
other symptom. Here, index visit means screening visit with
any given symptom reported for the ﬁrst time.
The reference group (screening visits without symptoms)
means visits with no reported breast symptoms in the screen-
ing history before the index visit for any given symptom. The
reference visit can later be the part of the exposure group if
symptoms occurred at future screening visits. Thus, symptoms
can be assumed of as a time-dependent covariate. Altogether
three sets of reference visits for each three symptoms were
formed by matching.
Matching
The frequency matching of the exposure groups to the refer-
ence groups were done by age at screening visit, year of invita-
tion, number of previous screening visits, and municipality of
invitation. Each visit with symptoms was matched to the via-
ble controls by random sampling. Assuming the effect size
and the power estimate of 0.80, the exposed-to-reference-visits
ratio was 1:1 for lump and retraction, and 1:2 for nipple
discharge.
Cause of death
Information on cause of death was derived from the Statistics
Finland database that categorizes disease according to Interna-
tional Classiﬁcation of Disease (ICD-7 until 1995 and ICD-10
from 1996) classiﬁcation. The underline cause of death was cate-
gorized using topography codes in the analysis: death resulting
from breast cancer (C50), and death resulting from other causes
(all ICD codes except C50). Information on socio-economic sta-
tus was only available for breast cancer cases and deaths.
Outcome assessment and follow-up
Incident breast cancer cases were deﬁned as new breast cancers
diagnosed in screened women after the ﬁrst invitation by the
programme. Breast cancer mortality means deaths due to breast
cancer diagnosed during the screening age-period after the ﬁrst
invitation by the programme. Women having cancer diagnosed
before the ﬁrst invitation by the screening programme were
excluded in the calculation of incidence (so-called incident-can-
cer) and mortality (so-called incidence-based mortality).17,18 All-
cause mortality means deaths due to any cause, including the
breast cancer cases, whereas, cause-speciﬁc mortality (except
breast cancer) refers to cases such as ‘mortality from other can-
cer’, and ‘mortality from other cause’. Follow-up for incidence
cases started from the index visit in 1 January 1992–31
December 2012 and ended at the date of cancer diagnosis or
emigration, or at the end of the follow-up – i.e. 31 December
2012 – whichever occurred ﬁrst. For interval cancer cases,
follow-up time was extended up to 31 December 2014. Simi-
larly, mortality follow-up started after the index visit in 1 January
1992–31 December 2012 and ended at the date of death (from
breast cancer or death from other cause) or emigration, or at
the end of follow-up – i.e. 31 December 2015. Deaths resulting
from breast cancer diagnosed during 2013–2015 were excluded.
Statistical analysis
Age-adjusted Cox proportional hazard regression models were
ﬁtted to compare the risk of breast cancer incidence and mor-
tality, separately for all-cause and cause-speciﬁc mortality,
among women with and without reported symptoms at the
index screen. The risks were estimated using hazard ratios
(HRs) and 95% conﬁdence intervals (CIs).
We also estimated the rates of breast cancer incidence, and
all-cause and cause-speciﬁc mortality, and compared between
the visits with and without symptoms. Incidence rates were
calculated as number of breast cancer diagnosed divided by
What’s new?
While breast cancer screening based on factors such as breast density and family history can signiﬁcantly reduce breast cancer
mortality, little is known about the importance of breast symptoms in screening programs. In this analysis of mammography
screening data collected from 1992-2012 in Finland, women who reported breast symptoms at screening had signiﬁcantly
increased risks of breast cancer incidence and mortality. For women who reported a lump or retraction, breast cancer incidence
was increased nearly two-fold and mortality three-fold. The ﬁndings suggest that improvements in screening and clinical
services are needed in Finland to better serve women with breast symptoms.
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the risk time, and compared between visits with and without
symptoms. Likewise, mortality rates were calculated as num-
ber of deaths divided by the risk time, and compared between
visits with and without symptoms. The rates and absolute dif-
ference in breast cancer incidence and mortality were reported
per 10,000 person-years of follow-up at 95% conﬁdence inter-
vals. For this, we categorized the follow-up time into 5-years
bands each. Instead, the cumulative hazards of breast cancer
incidence and mortality were reported using years as underly-
ing time units for risk time. The underlying time scale in all
the analysis was time since the visits with or without breast
symptom. The statistical difference in incidence and mortality
rates were reported using two-sided p-value. All statistical
analyses were conducted using Stata version 14.0 (STATA
statistical software, release 14; Stata Corporation, TX).
Results
A total of 6868 (4.5%) visits, out of 151,956 visits, were diag-
nosed as incident breast cancers during 1992–2012. Of these,
735 women (10.7%) died (during 1992–2015) from breast
cancer. The total follow-up time for incidence breast cancers
was 1,303,484.2 person-years, with a median of 3.1 years and
maximum of 20.7 years of follow-up, whereas, the breast can-
cer mortality follow-up time was 1,797,032.1 person-years,
with a median of 8.8 years and maximum of 22.3 years of
follow-up (Table 1). Table 1 shows the characteristics of the
ﬁnal study cohort.
The mean age at a screening visit, a cancer diagnosis, or a
death did not differ between visits with and without symptoms.
The follow-up time of breast cancer diagnosis or deaths result-
ing from breast cancer had wider variation between visits with
and without symptoms (median follow-up time of 1.9 versus
6.4 years for diagnosis and 8.1 versus 11.4 years for deaths, for
visit with and without lump). In women with a history of ﬁrst
cancer before the ﬁrst invitation, there was no signiﬁcant
(p-value >0.05) difference between visits with and without
symptoms. However, these women were later excluded to
compute incidence or mortality rates and rate ratios.
Figure 1. Flow diagram of study settings and outcomes. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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Breast cancer incidence and mortality rates in the
longitudinal follow-up
The rates of incident breast cancer cases were signiﬁcantly
higher (p-value = 0.000) within 5-years after the screening
visit (rate of 780 cases per 10,000 person-years versus 203 cases
per 10,000 person-years, for visits with and without lump)
(Table 2). Also, signiﬁcant difference (p-value = 0.000) in
overall rates (43.9 per 10,000 person-years, 95% CI 40.8 to
47.0; for visits with or without lump) were found between
visits with and without symptoms during the follow-up time.
Table 1. Cohort characteristics and outcomes
Characteristics
Lump Retraction Nipple discharge
Yes (%) No (%) Yes (%) No (%) Yes (%) No (%)
i) Attended previous
round
Yes 20,735 (49.1) 21,536 (50.9) 17,983 (49.2) 18,571 (50.8) 4686 (32.3) 9798 (67.7)
No 19,230 (51.1) 18,429 (48.9) 6207 (52.5) 5619 (47.5) 3196 (34.9) 5966 (65.1)
ii) Age at visit (mean, SD) 54.7 (4.3) 54.7 (4.3) 56.3 (5.2) 56.3 (5.2) 54.4 (4.5) 54.4 (4.5)
iii) Time difference between
index visit and breast
cancer diagnosis, in
years
Median
Range
1.92 6.42 1.50 3.58 4.17 4.34
0.04 to 20.7 0.08 to 20.3 0.04 to 11.2 0.08 to 11.3 0.08 to 17.7 0.08 to 19.0
iv) Time difference between
index visit and breast
cancer mortality, in
years
Median
Range
8.17 11.4 5.96 8.2 9.57 9.96
0.09 to 22.3 2.01 to 22.1 0.22 to 14.5 0.96 to 12.8 2.01 to 18.7 1.29 to 18.3
v) Time difference between
index visit and all-
cause mortality, in
years
Median
Range
10.50
.09 to 23.7
13.1
1.93 to 23.7
6.11
0.22 to 14.5
6.91
0.74 to 12.8
9.89
2.01 to 22.1
10.0
1.29 to 22.6
vi) History of breast cancer
or other cancers
before ﬁrst invitation
Yes
No
18 (69.2) 8 (30.8) 5 (55.6) 4 (44.4) 5 (45.4) 6 (54.6)
3185 (69.8) 1376 (30.2) 924 (63.6) 528 (36.4) 393 (45.9) 462 (54.1)
vii) Stage at diagnosis Localized
Non-localized
701 (82.6) 148 (17.4) 213 (71.9) 83 (28.1) 61 (55.9) 48 (44.1)
723 (90.5) 76 (9.5) 234 (82.7) 49 (17.3) 39 (52.0) 36 (48.0)
SD, standard deviation.
Values are numbers (percentage) unless stated otherwise.
Table 2. BC incidence in women who reported symptoms compared to asymptomatic women at screen
Outcomes Follow-up time, years
BC incidence
Incidence rate difference,
per 10,000 pyrs. (95% CI) p-value
Yes No
Pyrs. n rate1 Pyrs. n rate1
Lump 0–5 26,811.3 2092 780.3 27,330.9 556 203.4 43.9 (40.8–47.0) 0.000
More than 5–10 61,338.9 497 81.0 62,936.8 360 57.2
More than 10–15 69,490.4 379 54.5 72,622.2 291 40.1
More than 15–20 199,153.6 210 10.5 215,123.2 168 7.8
More than 20–25 64,665.7 7 1.1 56,388.9 1 0.2
Total 421,459.9 3185 75.6 434,402.0 1376 31.7
Retraction2 0–5 28,635.9 745 260.2 28,876.0 354 122.6 31.0 (25.3–36.7) 0.000
More than 5–10 64,727.6 165 25.5 66,430.5 157 23.6
More than 10–15 37,238.1 14 3.8 37,568.4 17 4.5
Total 130,601.6 924 70.7 132,874.9 528 39.7
Nipple discharge 0–5 8048.6 222 275.8 16,123.6 251 155.7 27.1 (19.9–34.3) 0.000
More than 5–10 17,745.2 103 58.0 35,476.7 132 37.2
More than 10–15 17,456.6 50 28.6 35,040.2 64 18.3
More than 15–20 15,732.9 18 11.4 33,915.2 15 4.4
More than 20–25 2080.0 0 0.0 3434.7 0 0.0
Total 61,063.3 393 64.4 123,990.4 462 37.3
1Rate per 10,000 person years of follow-up.
2Information on retraction was started to collect during late 1990s.
Abbreviation: CI, conﬁdence interval.
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Similar differences (p-value = 0.000) in the incidence rates of
cancer diagnosis or deaths were observed for retraction
(31 per 10,000 person-years, 95% CI 25.3 to 36.7) and nipple
discharge (27.1 per 10,000 person-years, 95% CI 19.9 to 34.3)
as compared to respective asymptomatic visits.
The breast cancer mortality rates greatly differ (p-value =
0.000) within 5-years between visits with and without symp-
toms (77.7 deaths per 10,000 person-years versus 8.4 deaths
per 10,000 person-years, for visits with and without lump)
(Table 3). Likewise, the overall differences in mortality rates
were signiﬁcant (p-value = 0.000) for lump (5.3 per 10,000
person-years, 95% CI 4.4 to 6.1) and retraction (2.9 per
10,000 person-years, 95% CI 1.9 to 3.8) as compared to
respective visits without symptom. But, no signiﬁcant differ-
ence (p-value = 0.226) in mortality rate (0.75 per 10,000
person-years, 95% CI minus 0.51 to 2.0) was found for
nipple discharge as compared to those without symptom.
In addition, the all-cause mortality rate differ signiﬁcantly
(p-value<0.05) in all symptom types as compared to respective
asymptomatic visits. Interestingly, we found more cases of
other cause death than breast cancer, long (after 10 years of
follow-up) after the visits with or without lump, which was
quite opposite when the cause of death was a breast cancer.
Risk of breast cancer incidence and mortality
The risk of dying from breast cancer was signiﬁcantly higher
in those who reported lump (age-adjusted hazard ratio 3.1,
95% CI 2.5 to 3.7) and retraction (age-adjusted hazard ratio
3.8, 95% CI 2.4 to 6.2) compared to respective asymptomatic
group (Table 4). For nipple discharge, the risk of breast cancer
was not signiﬁcant (age-adjusted hazard ratio 1.4, 95% CI 0.82
to 2.4), but the risk of all-cause mortality was signiﬁcantly
higher (age-adjusted hazard ratio 1.5, 95% CI 1.04 to 2.2) than
those visits without nipple discharge.
Cumulative incidence and mortality rates per 10,000
person-years of follow-up
The incidence of breast cancer increased rather rapidly after
the visit with a lump, whereas, the breast cancer mortality or
all-cause mortality risks increased within 5-years after a visit
with lump (Figs. 2a–2c). Similar patterns of increased (inci-
dence and mortality) risks were found in visits with a retrac-
tion or nipple discharge (incidence only), as compared to
visits without respective symptom. Considering the cumula-
tive risk of breast cancer mortality in respective visits without
lump and retraction as a reference, the same level of risk was
reached within a half of the follow-up time in visits with lump
and retraction, respectively. However, no such difference in
mortality risk was evident for nipple discharge.
Discussion
Our study demonstrated that women who reported symptoms
at screening visit had higher risk of breast cancer incidence
and mortality. Women who reported lump or retraction had
about two-fold risk of breast cancer incidence, three-fold risk
of breast cancer mortality and all-cause mortality respectively
as compared to women without respective symptoms. The
cumulative mortality patterns, breast cancer mortality and all-
cause mortality, remained higher in symptomatic women in
the long follow-up time available in our study. These ﬁndings
indicate an urgent need to develop improvements in the
guidelines on screening and clinical services for women pre-
senting with symptoms. To our knowledge, our study is the
ﬁrst to assess the association between symptoms and
mortality risk.
Strength and limitations
Our study ﬁndings are based on valid collection of informa-
tion with reliable linked data at national level. We used a pro-
spective study design and included all-visits with symptoms
and similar number of asymptomatic visits from the whole
women population of the targeted age who attended for
screening mammography. We followed women for 24 years
and collected information on breast symptoms biennially, thus
it was possible to accurately assess association of symptoms
with the subsequent risk of breast cancer or death. Individual
level data from several sources: screening reports, patient or
hospital records, death reports, autopsy reports, etc. were
linked using unique personal identiﬁer. The exact date of
reporting of symptoms, date of diagnosis or death or emigra-
tion were known for every subjects, thus, the calculated
follow-up time intervals were precise. Matching symptomatic
visits by background variables to asymptomatic visits have
made the two groups comparable at any given period (maxi-
mum 10 visits) of screening visits. Because of the large cohort,
the study power was sufﬁcient to compute the difference in
risk and rates for every individual symptoms with respective
asymptomatic visits.
Our study has potential limitations. our study is based on
the database research and information about important risk
factors such as family history, breast density and socio-
economic status was not collected, and thus it was not possi-
ble to ﬁnely adjust for potential confounders. We do not know
about delay in presentation of symptoms on whether women
waited for her ﬁrst (i.e. at age 50 years) or subsequent screen-
ing invitation. Our analysis of symptoms was based on
women’s reporting of symptom during the past two to six
months and the examination by the radiographer or nurse at
the screening visit. Thus, the collected symptom information
is valid with negligible recall bias. The attendance bias because
of symptomatic women were more likely to attend for screen-
ing than asymptomatic women cannot be ruled out. However,
the high screening attendance proportion (84% among those
invited) in the Finnish mammography screening programme
and 99% of the attendees are asymptomatic, the attendance
bias is likely to be negligible. In addition, we did not ﬁnd any
difference in the attendance proportion and risk of breast
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cancer between ﬁrst and subsequent visit in women with or
without symptoms.
The all-cause mortality rates were relatively higher than
breast cancer mortality, and the substantial difference in rate
was found between symptomatic and asymptomatic group
throughout the follow-up period. In absolute terms, for lump,
in every 10,000 person-years of follow up, 180 women died
from breast cancer as compared to 70 women without lump,
and 315 versus 160 all-cause deaths in women with and with-
out lump respectively after 24 years of follow-up. We also
found difference in the number of deaths in women who
reported retraction or nipple discharge. The difference in all-
cause mortality was not related clearly to other speciﬁc causes
of death than breast cancer, but differences in deaths from
other causes than breast cancer were related to several causes.
It is likely that having a lower socio-economic status can par-
tially affect the ﬁndings on symptoms, affecting therefore also
to mortalities from breast cancer as well as of several other
causes. We observed extra (all-cause) death cases in women
who reported a lump in lower socio-economic class than
higher class, and surplus number of deaths as compared to
those without lump. In our study, the socio-economic status
of the whole cohort is unknown, thus, the proportion of breast
cancer deaths or all-cause deaths in those with or without
symptoms might differ from our ﬁndings.
Clinical and public health implications
All three symptoms analyzed in our study provides new evi-
dence on the risk of breast cancer incidence and mortality.
Information on breast symptoms reported by the women should
Table 4. Association between symptoms and mortality as compared to those without symptoms
Symptom
BC incidence BC mortality All-cause mortality
Age-adjusted hazard ratio (95% CI) Age-adjusted hazard ratio (95% CI) Age-adjusted hazard ratio (95% CI)
Lump 2.37 (2.23–2.53) 3.14 (2.59–3.79) 2.72 (2.35–3.17)
Retraction 1.77 (1.59–1.97) 3.88 (2.40–6.27) 3.27 (2.25–4.75)
Nipple discharge 1.73 (1.51–1.97) 1.40 (0.82–2.39) 1.52 (1.04–2.22)
Abbreviations: BC, breast cancer; CI, conﬁdence interval.
Figure 2. (a-c): Cumulative incidence of (a) breast cancer, (b) breast cancer mortality and (c) all-cause mortality per 10,000 person-years of
follow up. Note: The conﬁdence intervals lines for cumulative incidence are indicated by light dotted lines in symptomatic and asymptomatic
groups. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
2934 Breast symptoms in screening mammography
Int. J. Cancer: 144, 2928–2935 (2019) © 2018 UICC
C
an
ce
r
E
pi
de
m
io
lo
gy
not be ruled out or ignored. Neither the evidence should only
be used to support the interpretation of the mammography
ﬁndings as done until now. The substantial high mortality rates
within 5-years after the visit with symptoms demands proper
further assessment of screening visits with symptoms irrespec-
tive of the mammography ﬁndings. The radiographers or nurses
should properly examine the women who present with breast
symptoms.
The design of the Finnish programme to screen women
with symptoms differs substantially from other programmes.
The EU guidelines mention that screening invitation should
be of unselected target population and sufﬁcient attention is
paid to symptomatic details provided by the women.13 It
would be very important to record ﬁndings of these women
also to a separate report of the screening programme. Many
screening programmes refer symptomatic women directly to
hospital or special breast clinics, thus they do not consider
ﬁndings for those referred women as a part of the screening
programme.11,12,19,20 However, clinical check-up still may miss
cancers and may not have as good opportunities for systema-
tical follow-up than the screening programme. One thing is
clear that collection of symptoms information in the Finnish
programme is completely based on the invitation to screening,
thus, no diagnostic mammography results (based on clinical
presentation of symptoms) are discussed here. Not consider-
ing these women as a part of the screening mammography by
the other programmes might have important consequences,
such as validity of programme evaluation since a signiﬁcant
proportion of women with symptoms might left out, and
assessing those outside the programme may demand for addi-
tional resources.21 A better option is to request for better
recording and reporting of the symptoms information from
the radiologists or nurses with additions of information
(requesting women also) on duration and severity of pain21 or
other possible ﬁndings based on palpation. Also, awareness of
breast symptoms and importance to seek diagnostic services
already prior invitation to screening is important. On the
other hand, referring all women with symptoms might cause
additional false-positive cases, lower efﬁcacy of the pro-
gramme, and anxiety or other psychological distress to the
women. The health economic assessment of providing such a
comprehensive service to all screening visits with symptoms
should be made, thus warrant attention for future research.
In conclusion, our study provided comprehensive evidence
that women with breast symptoms such as lump, retraction
remain in a higher risk of developing breast cancer during the
rest of their lifetime. In addition, the risk of dying from breast
cancer was in excess over a very long period; and, astonish-
ingly also the overall mortality risk. The later ﬁnding might
relate to low socio-economic status or other such barrier in
the awareness and/or access to services. The collected symp-
toms information should extend to long-term evaluation also
in other settings, and the development of guidelines to reduce
these inequities.
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